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Abstract. A human gene termed XB overlaps the 
P450c21B gene encoding steroid 21-hydroxylase and 
encodes a protein that closely resembles extracellular 
matrix proteins. Sequencing of phage and cosmid 
clones and of cDNA fragments hows that the XB 
gene spans 65 kb of DNA, consisting of 39 exons that 
encode a 12-kb mRNA. The predicted protein of over 
400 kD consists of five distinct domains: a signal pep- 
tide, a hydrophobic domain containing three heptad 
repeats, a series of 18.5 EGF-like repeats, 29 fibronec- 
tin type HI repeats, and a carboxy-terminal fibrinogen- 
like domain. Because the structure of the protein en- 
coded by the XB gene closely resembles tenascin, we 
term this protein tenascin-X (TN-X), and propose a 
simplified nomenclature system for the family of 
tenascins. RNase protection experiments show that the 
TN-X transcript is expressed ubiquitously in human 
fetal tissues, with the greatest expression in the fetal 
testis and in fetal skeletal, cardiac, and smooth mus- 
cle. Two adrenal-specific transcripts, P450c21B (ste- 
roid 21-hydroxylase) and Y (an untranslated transcrip0 
overlap the XB gene on the complementary strand of 
DNA, yielding a unique array of overlapping tran- 
scripts: a "polygene: In situ hybridization histochemis- 
try experiments show that the TN-X transcript and the 
P450c21 and Y transcripts encoded on the com- 
plementary DNA strand are all expressed in the same 
cells of the human adrenal cortex. Genetic data sug- 
gest that TN-X may be essential for life. 
T 
ENASCIN, a large glycoprotein of the extracellular 
matrix, has been studied extensively for about 10 
years (for review see reference 11). Each of the six 
monomers that constitute nascin exists in multiple size vari- 
ants of 220-320 kD and contains four domains. The amino 
terminus comprises the hydrophobic "head group; which 
facilitates polymerization i to the tenascin hexabrachion; 
this is followed in turn by a series of EGF-like repeats, a se- 
ries of fibronectin type III (Fn HI) t repeats, and a carboxy- 
terminal fibrinogen-like domain (11, 16, 22, 41, 52, 58). 
Tenascin appears to mediate interactions between cells and 
the extracellular matrix (and possibly between cells) (7, 47), 
through an RGD-dependent (3, 29) or -independent (46, 52) 
receptor. Initial studies uggested a crucial role in embryonic 
development (6, 53, 58), although recent tenascin gene 
knockout experiments in transgenic mice suggest that enas- 
cin serves no mandatory, irreplaceable role in development 
or in the adult (48). Tenascin appears to be one member of 
a family of related proteins, encoded by related genes. Each 
family member has the same general structure as tenascin: 
NH2-head group-EGF domain-Fn HI domain-fibrinogen 
1. Abbreviations used in this paper: Fn IU, fibronectin III; TN-X, terms- 
cin X. 
domain-COOH. In addition to tenascin, a closely related 
protein termed restrictin (42) or J1-160/180 (13) has a similar 
structure. The structure of undulin, which contains a yon 
Willebrand factor domain at the NH~ terminus followed by 
Fn I~ repeats (23), indicates that here are variations on this 
theme. 
We now describe the gene structure and tissue distribution 
of another member of this family termed tenascin X (TN-X), 
which is encoded by an unusual gene termed XB in the 
human major histocompatibility locus. This gene was dis- 
covered because it overlaps the gene encoding steroid 21- 
hydroxylase (39), and was later shown to encode a tenas- 
cin-like sequence (14, 60; Bristow, J., S. E. Gitelman, Y. 
Shi, and W. L. Miller, 1990. Pediatr. Res. 27:76a). Recent 
preliminary reports from another group have confirmed this 
(30) and extended the findings to show that his gene has the 
expected EGF-like domain (31). In addition to overlapping 
the P450c21B gene (formally designated CYP21B) (40) en- 
coding steroid 21-hydroxylase, the human XB gene also ex- 
tensively overlaps the YB gene (see Fig. 1), which encodes 
an untranslated a renal-specific RNA (4). In this paper, we 
delineate the organization, sequence, and tissue distribution 
of expression of the XB gene. Furthermore, we propose a 
unified nomenclature system for these various tenascins and 
assign the name TN-X to the product of this new gene. 
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Materials and Methods 
Genomic and cDNA Library Screening 
Genomic libraries prepared from human leukocyte DNA in h-DASH, and 
h-Charon 4A were plated at a density of 3 × 105 pfu/plate. Duplicate lifts 
onto nitrocellulose filters were made and cross-linked by baking. A cosmid 
library in pWE15 (Stratugene, San Diego, CA) and a cDNA library in MZAP 
(4) were plated at 5 × 105 colonies/plate, and duplicate replica filters were 
made and processed by standard procedures. All filters were probed in 50 
mM Tris (pH 7.5)•50% formamide/5× SSC/I× Denhardt's solution/0.1% 
NaDodSO4, at 42"C, with probes labeled to a specific activity of>5 × l0 s 
cpm/#g using random primers (Pharmacia Fine Chemicals, Piscataway, 
NJ). Washing was carried out in 0.1% SSC/0.1% NaDodSOa for 10 min at 
room temperature and for 30 min at 65"C. Positive plaques were picked and 
purified further by two additional rounds of plating and probing. Bacterio- 
phage DNA was prepared by the method of Helms et al. (17). Cosmid DNA 
was prepared by alkaline lysis. 
DNA Sequencing 
Genomic and eDNA fragments for sequencing were subcloned into pBlne- 
script KS or SK vectors (Stratagone) and purified over a CsCl/ethidium bro- 
mide gradient. Sequencing was done on double-stranded t mplates (5) with 
Sequcnase (United States Biochemical, Cleveland, OH) and 35S-labeled 
dATP as recommended bythe manufacturer, except hat termination reac- 
tions were carried out at 420C. Reaction products ware analyzed by elec- 
trophoresis on 5 % polyacrylamide g ls containing 7 M urea, and subse- 
quent autoradiography. Coding regions and portions of all introns of the XB 
gone, and the entirety of all cDNAs were sequenced on both strands. Se- 
quences were analyzed with the DNA Inspector (TEXTO, West Lebanon, 
NH) and the "Eugene" sequence-analysis oftware (Molecular Biology In- 
formation Resource, Baylor College of Medicine, Department of Cell Biol- 
ogy, Waco, TX). Phylogenetic analysis of Fn HI repeats was performed 
using the PAUP program (Swofford, D. L., Illinois Natural History Survey, 
Champaign, IL, 1991). 
Reverse Transcription/Polymerase Chain 
Reaction (RT/PC R ) 
Human fetal tissues were quickly frozen in liquid N2, and total RNA was 
prepared by homogenization in 4 M guanidinium thiocyauate, followed by 
ultracentrifugation over a 5.7 M CsCI cushion, as described (33). Pellets 
were resnsponded in 10 mM Tris-HC1 (pH 7.6)/1 mM EDTA/0.1% 
NaDodSO4 extracted twiee with phenol/CHC13, precipitated with ethanol, 
quantitated byadsorption spectrometry at A26o/A280, and stored in ethanol 
before use. PolyA + RNA was obtained by oligo-dT chromatography. Ran- 
dom hexamers were used to prime eDNA synthesis from 100 ug of poly- 
adenylated RNA or 2 #g of total RNA using Superscript reverse transcrip- 
tase (Bethesda Research Laboratories, Gaithersburg, MD) for 1 h at 42"C. 
Aliquots of eDNA were amplified by PCR using Taq polymerase 0BI, New 
Haven, CT) and specific oligonueleotide primers based on the sequences 
of various cosmid subelones. PCR products were subcloned into pBlue- 
script (Stratagene) or pCRII (invitrogen, San Diego, CA) for restriction 
mapping and DNA sequencing. 
Rapid Amplification of eDNA Ends 
Rapid amplification of eDNA ends (RACE) was performed as described 
(12) using a reagent kit (Bethesda Research Laboratories); eDNA synthesis 
from 2 #g of total muscle RNA was primed with a gene-speeifie antisense 
primer and reverse transcribed at42"C for 1 h. After removal of the initial 
primer and RNA, the eDNA was tailed with dCTP and terminal transferase. 
Subsequent PCR used nested antisense primers and a 5' adaptor primer. 
PCR products were subcloned into pBhiescript for sequence analysis. 
RNase Protection 
RNaso protection experiments were done essentially as described (14). For 
RNase protection of XB gene transcripts, relevant genomic or eDNA flag- 
ments were subeloned into pBluescript and lincarized. An antisense probe 
was synthesized with 32p-uTP using bacteriophage T7 RNA polymerase. 
After purification, the probe was hybridized to 15 #g of total RNA in 80% 
formamide/50 mM PIPES (pH 6.4)/0.4M NaCI/1 raM EDTA overnight at 
42"C. Single-stranded RNA was digested with 5-8 #g of DNase-free RNase 
A (BoehringeryManlaeim , Indianapolis, IN) and 50 U RNase T1 (Pharma- 
eia, Piscataway, NJ) at 37"C for I h, and the protected fragments were sepa- 
rated by electrophoresis on a 7% polyacrylamide gel containing 7 M urea. 
In Situ Hybridization Histochemistry 
Probes for in situ hybridizations were synthesized from linearized pBlue- 
script plasmids containing eDNAs for human P450scc (8), P450c21 (32), 
TN-X, and Gene Y (4). Antisonse ribopmbes labeled with 3sS-labeled 
UTP were synthesized with T3 or T7 RNA polymerase as described for the 
RNase protection probes. 
Human tissues (20-23-wk gestation) were obtained through approved 
protocols of the UCSF Department ofObstetrics, Gynecology and Repro- 
ductive Sciences at the time of elective cervical dilatation and evacuation. 
Tissues were transported in medium 199 on ice, dried to remove excess 
moisture, and frozen in Tissue Tek O.C.T. Compound (Miles, Inc., Elk- 
hurst, IN) in a methanol/dry-ice bath. 10-#m sections were cut with a 
eryostat, collected onto microscope slides, and coated with a gelatin ehrom 
alum mixture (0.4%/0.04% wt/vol). Frozen sections were fixed for 5 rain 
in 4% paraformaidehyde in PBS, pH 7.4, and dehydrated in 70 and 100% 
ethanol. Dried sections were stored with desiccant at -700C, then treated 
with proteinase K (2.5 #g/ml in 2× SSC) at 37"C for 15 rain, rinsed in 2× 
SSC, and acetylated for 30 rain as described (34). Probes were boiled for 
5 rain and applied to tissue sections at 100 pg/mi n prehybridization solu- 
tion 50% formamide, 4× SSC, Ix Denhardt's solution, 140 #g/mi heparin, 
25 #g/ml denatured Escherichia coli DNA, 2.5 #g/ml polyadenylic acid, 
and 100 mM DTT, and then hybridized overnight in a humidified environ- 
ment at 37"C. Slides were washed twice for 15 min at 37"C in 2× SSC con- 
taining 100 mM B-marcaptoethanol, twice for 15 rain at 37"C in 0.5× 
SSCflO0 mM B-mercaptoethanol, and once for 15 rain in 2× SSC at 37"C. 
Slides were then treated with 20 #g/ml RNaso A in 2× SSC at 37"C for 
30 min, washed one final time in 2× SSC for 15 rain at room temperature, 
and coated with llford K-5 nuclear emulsion diluted 1:1 with 2 × SSC. Slides 
were stored at 4"C, developed after 2 wk of autoradiography, and counter- 
stained with cresyl violet to define tissue architecture. 
Results 
Arrangement of the Gene Cluster 
Tenascin X is encoded by the large XB gene in the class HI 
region of the major histocompatibility locus. This gene is 
part of a complex array of genes encoding the fourth compo- 
nent of serum complement (C4), the form of cytochrome 
P450 having steroid 21-hydroxylase activity (P450c21), and 
a transcript of unknown function operationally termed gene 
Y (4, 14, 36, 39). This locus is duplicated in the human ge- 
nome, resulting in the complex array of genes shown in Fig. 
1. We initially discovered the X genes overlapping the 3' ends 
of the P450c21 genes by cloning a 2.7-kb eDNA fragment 
identified with a P450c21B eDNA probe (39). The 2.7-kb 
eDNA is encoded by the large XB gene; the XA gene in turn 
was truncated by the nonhomologous recombination event 
that led to the duplication of the human gene cluster, so that 
it does not appear to encode protein (14). By contrast, the 
XB gene appeared to encode a 12-kb RNA (14), which in 
turn encoded a protein resembling the extracellular matrix 
protein tenascin (14, 60). 
Structure of the XB Gene 
To clone the XB gene, we first screened a human genomic 
DNA library in k-Dash using a 1.8-kb BamHI/EcoRI frag- 
ment of the 2.7-kb XB eDNA (39). This probe, which was 
chosen because it excluded the regions overlapping P450c21, 
identified kXB-1 as an XB genomic lone. This clone hybrid- 
ized to an 850-bp PstI/EcoRI fragment from the 5' end of the 
2.7-kb X eDNA and did not hybridize to a P450c21-specific 
eDNA fragment or a 5' C4A eDNA (Fig. 1). Probing of a 
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Figure 1. Map of the XB gene-encoding TN-X. (A) Organization fthe duplicated C4/P450c21/X/Y locus on the short ann of human chro- 
mosome 6; the centromere is to the left and the telomere to the right. The upper line shows the scale in kilobases. The diagram shows 
the TN-X and XA genes as hatched boxes, the P450c21 genes (21A and 21B) as black boxes, and the Y genes as open boxes. The arrows 
indicate transcriptional orientation. In B, the TN-X gene is enlarged to show its exon/intron structure (note the scale marker at the left). 
The upper lines show the extent of the genomic DNA in the various lambda phage (X) and cosmid (c) clones discussed in Results. The 
exons of the TN-X gene are shown as boxes, and the Roman umerals below the line identify the Fn lIl repeats, cDNAs are indicated 
as horizontal bars over the relevant exons. Exon 1 encodes the leader peptide and heptad omain; exon 2 encodes the EFG-like repeats, 
exons 3-34 encode the 29 Fn 111 repeats, and exons 35-39 encode the fibrinogen-like domain. Note that Fn m repeats ii, xxvii, xxviii, 
and xxix are each encoded by a pair of"split" exons, while repeats viii and ix are encoded by a single "fused" exon. A map of the BamI-II 
and EcoR/restriction sites is shown below. (C) Diagram of the structure of a TN-X monomer, using the symbols popularized by Spring 
et al. (52). The five "balloons" on the heptad, on Fn III repeat xxviii, and on the fibrinogen-like domain (FG) designate potential N-linked 
glycosylation sites. 
Southern blot of multiple restriction enzyme digests of 
kXB-1 with the 1.8-kb eDNA probe revealed a7-kb BamHI 
fragment and other RFLP markers predicted to be in the 
DNA Y of the P450c21B gene (45). DNA sequencing could 
be initiated by a 20-mer corresponding to the 5' end of the 
2.7-kb eDNA, further confirming that phage kXB-1 cor- 
responded to the XB region, and that the 2.7-kb eDNA was 
encoded by XB. 
Mapping of kXB-1 showed it contained 11 kb of human 
DNA. Sequencing ofthis DNA showed the 2.7-kb eDNA was 
encoded by 15 exons spanning 6.6 kb (sequence included in 
Fig. 2). We found only two bona fide nueleotide differences 
between the gene and the cDNA. One of these differences 
was in the third position of a codon and does not result in 
an amino acid change, while the other results in a substitu- 
tion of isoleueine for valine (amino acid number 3260 in Fig. 
2). A sequencing error (bases 25,817-25,819 in Fig. 2) was 
also detected. The intrordexon junctions matched the GT/AG 
rule perfectly, and showed no evidence that the 2.7-kb eDNA 
corresponded to an alternately spliced mRNA. 
kXB-1 also contained the 5' portion of the exon encoding 
the 5' end of the 2.7-kb eDNA, thus slightly extending the 
open reading frame. However, Northern blots suggested that 
the XB transcript might be substantially longer. To elucidate 
the sequence of XB, we then screened two additional human 
adrenal eDNA libraries, a human testis eDNA library and 
a human placenta eDNA library with 5' fragments of the 2.7- 
kb eDNA; all of these yielded 3' fragments of XB eDNA, 
but none was longer than the original 2.7-kb clone. There- 
fore, we extended our knowledge of XB by sequencing the 
XB gene. 
Sequencing of the remainder of the 5' DNA in hXB-1 re- 
Bristow et al. Tenascin-X 267 
1: CA~GCACG~GCA~G~CACTG~GCTGC~CGGTTGCCCAGCCT~T~d~T~ATG~GCCCAGTATG~TCT~CCTC~GCC~G~TT~TCCT~GTGCTGCTGAGCACAGCC~GAGC&GGCCC~TTCTCTTCA 
i: M M P A Q Y A L T S S L V L L V L L S T A R A / G P F S S  
133: CGGTC~TGT~ACTG~GCCCCCCGG~CCCTCCCCAG~CAGGGGG~CACAGTGGGGGCTG~AGTGGG~GCCCCTCTTCT~A~TTTAc~GCACACAGTGG~GGAGGGGAG~G~AGGTGGTA 
2 9 : R S ~ V T L P A P R P P P Q P G G H T V G A G V G S P S S Q L Y E H T V E G G E ~ O V V  
265: TT~C~C~GCATT~C~TG~CCCTT~CTGGCTGTGGCTGTC~AGG~CCGAGCCCC~GT~CTTGCTTCA~GGTA~AGG~cT~GGGTCCGT~TAGAGATCCTGGAG~GTTGGTGAA~GGG 
7 3 : F T H R I N L P P S T G C G C P P G T E P P V L A S E E O A L R V R L E I L E E L E K G  
397: CTCAAGGAACAGTGCACTGGGG~TGTTGTCCTGCCTCTGCCC~GCTGCCACAG GTGAGCACGT~TCA~GAAGAGCGTGGA~GGTGGCGTGCGGTGCCCATTGCTAGTCCATAAAGGTCCTTGGTATG 
I l T : L K E O C T G G C C P A S A Q A C T  
529: ~TTAGAA~AAGGCA~T~TTCCT~C~GT~GGGGTGTG~TG~G~GAACACAACTTG~GAG~A~GCTGGGCTACATGT~C~AAAGCATATGCGAGGG~CCT~GGCTG~ATA~ATTA~AC 
661: ATACTAGC~TGGGAG~A~¢~TGG~TTATGA~T~GGCTAGC~TGGCTAGGGGC~TGA~A~TA~GAGCACTAC&TAGG~T~AG~TCTCTCCCAGG~GA~AGA~T~GACTTGCCT~TC~T~TA~ 
793: TCCAG GT~GA~GAT~T~C~C~T~T~CAGT~TC~ATGGTGT~TTT~AT~T~AGCCGCT~TGTTC~TGT~GCCAGG~TG~GGTGG~C~CA~CT~T~AGAC~ACAGATGCTGA~T~cTCC 
135: G O T D V R T L C S L H G V F D L S R C T C S C E P G W G G P T C S D P T D A E I P P  
925: cTCTT~CC~CCCTcAGCCTC~GTCCTGCCCA~T~CTGCAAT~TCAGGGTCGCTGTGTCCGTGGT~GTTG~GTGTGCTTTCCCGGCTACACTGGCCCCAGCTGTGGCTGGCCATCCTGTCCCGGGGA 
1 7 9 : S S P P S A S G S C P D D C N D Q G R C V R G R C V C F P G Y T G P S C G W P S C P G D  
1057: ~TG~C~GGC~GTGGG~GCTGCGTG~AGGGCGTGTGTGTGTG~GGG~AGGCTTCT~GG~CC~CTG~AG~GCGCTCCTGCCCTCGAGGTTGCAGCCAGAGGG~cGCTGTGAGGGTGGGCGCTG~GT 
2 2 2 : C O G R G R C V Q G V C V C R A G F S G P D C S O R S C P R G C S O R G R C E G G R C V  
Ii~9: GTGT~CC~GG~TA~ACTGGT~CGACTGTGG~ATGAGGAGCTGCcCT~GCGGTTGCAGT~A~GGGGCG~T~TGAGAATC~GCGCTGCGTGTGT~C~cCGGCTACACTGGCGAGGAcT~TGGGGT~G 
2 6 6 : C D P G Y T G D D C G M R S C P R G C S O R G R C E N G R C V C N P G Y T G E D C G V R  
1321: ~GCTG~CcTCGGGGCT~AGCCAGCGGG~CGCT~C~ACGGGCGCTGCGTGTGTGACCCCG~CTACA~TGGCGAGGACTGT~GTAC~CGGAGCTGCCCCTGGGACTGTGG~GAGGGCG~CGCTGCGT 
3 1 0 : S C P R G C S Q R G R C K D G R C V C D P G Y T G E D C G T R S C P W D C G E G G R C V  
1453: G~CGGc~GCTGCGTGTGCTGGCCCGGGTACACAGGC~G~CTG~AG~ACGCGGACATGTCCGAGGGACTGCCGGGGCCGCGGGCGCTGCGAGGACGGCG~TGCATTTGCGA~CGGGCTA~AGCGGGGA 
3 5 4 : D G R C V C W P G Y T G E D C S T R T C P R D C R G R G R C E D G E C I C D T G Y S G D  
1555: C~T~GGCGTGCG~G~TG~cCTGG~GAcTGCAA~CAAAGGGGC~GcTGC~G~cGGC~G~TGCGTGTGCTGGCCGGGGTA~CTGGAACcGATTGCGG~TC~GCGC~TGcC~ACG~CTGTA~GG 
3 9 0 : D C G V R S C P G D C N Q R G R C E D G R C V C W P G Y T G T D C G S R A C P R D C R G  
1717: TCGCGGGC~TGC~GAA~GGCGTGTGTGTTTGCAATG~GG~CTACAGCGGC~G~CT~CGGTGTG~GcAGCTGTCCTGG~CTGTCGTGGCCGGGGCCGCTGTGAGAGTGG~CGCTGCATGTGTTGGCC 
4 4 2 : R G R C E N G V C V C N A G Y S G E D C G V R S C P G D C R G R G R C E S G R C M C W P  
I~49: GGGGTA~GG~GG~T~GG~C~G~TGTCCTGGCGA~TGTCG~GGGCG~GGGCG~TG~GTG~TGGCCGCTGCGTGTGc~CCcGGGCTTcAC~GGT~GGA~TGTGG~GC~GT~GCTGTC~ 
4 $ 6 : G Y T G R D C G T R A C P G D C R G R G R C V D G R C V C N P G F T G E D C G S R R C P  
1951: ~GG~TG~GTGGGCACGGCCTTT~GAG~TGGcGTGTGC~TGTGTGACGCA~GCTACTCAGGGG~CTGCAGCACGCG~AGCTGCCCCGGGGGCTGCCGA~G~CGCGGCCAGTGC~TA~TGGG~G 
5 3 0 : G D C R G H G L C E D G V C V C D A G Y S G E B C S T R S C P G G C R G R G ~ C L D C R  
2113: GTGTGTGTGCGAG~CGGCTACTCTGGCGAGGATTGCGGTGT~AGGCAGTGCCC~TGACTGCAGCCAGCACGGCGTGTGCCAGGACGGTGTGTGCATCTGTTGGG~GGCTAcGTGAGTGAGGACTGCAG 
5 7 4 : C V C E D C Y S G E D C G V R Q C P N D C S Q H G V C O D G V C I C W E G Y V S E D C S  
2245: ~AT~CG~C~TG~CT~CTG~CA~GG~GGGGC~GCTGTGAGG~AGGGCGCTGCCTGTGC~C~CAGGCTACACCGGCCCTA~CTGTGCCACCCGCATGTG~CGGCTGAcTGCCGGG~CGTGGGCG 
6 1 $ : I R T C P S N C H G R G R C E E G R C L C D P G Y T G P T C A T R M C P A D C R G R G R  
2377: GTGTGTG~G~TGTG~TGTGCCACGTGGGCTATGG~GGTCAGGACTGCGGGCAGGAAGAGCCTCCAGCCAGCGCCTGCCCTGGAGCCTGC~GGCCCCGGGAA~TGTGCCGGG~AGGCCAGTGTGTGTG 
6 6 2 : C V O G V C L C H V G Y G G E D C G O E E P P A S A C P G G C G P R E L C R A G O C V C  
2509: TGTA~GGGCTTCCGAGG~CT~CTGTGCCATCcAGACATGCC~AGGG~CTGCCGTGGCCGAGGAGAGTGTcACGATGGCAG~TGTGTCTGcAAAGATGGGTATGCTGGCG~GACTGCG~G~G GT A 
7 0 6 : V E G F R G P D C A I O T C P G D C R G R G E C H D G S C V C K D G Y A G E D C G E  
2641: G~GGCAGCCTTCCCCAGTGTACTCTGG a~ut  6kb ~A~T~cTGGCAGATG~CACGGCGTG~CCATGAGAGGG~CTCTGACAGATAAATAGGGGGTGCCCATGAGAGGGGACT~TGGGATC 
2773: A~AcTGCTAGGG~T~"~ATTCTTGC~ATTTTCTTGGTGTTGGTGACGTTGGCAAGATA~TTGTC~TT~TGTGTCT~AGTTT~CTTATCTGTAAAATGG~CT~TAG~TGTTT~GTAGGGTTGTTGTGA 
2905: GAATT~GT~GTT~AT~TGTGTA~CTC~TA~AA~AGTGGCT~C~GGAGTTAGCGCTCTCAGCATGTTTGCTCCCCAGCTTGTG~G~GTC~GTTC~ACACAGTAC~ATGCT~A~TGTTTAGAAT 
3037: TTGGAGAAAGAA~GAT~GGGGGATTGGAGCAG~GAGGC~AGTGC~AGCcC~TGAGCCA~CTGGTG~TCTCTCT~CAAGA~AGAGGGGGGG~GCCCCCATTcAC~G~GGGTTCCCAG a~ut 
3169: 100 bp ACTA~GGG~CCTC~CT~GGG~GGGCAAGAAGGAAGGG~TGGATGGGGcCTAGGCTCTT~GAAGGA~AGAT~TGATTGAAGAA~CAGA~C~T~TCCT~CTCTTT~ 
3301: CCTGGCTAG TGATC~TGGCCCC~G~CT~c~GTGGTGTCTGTGA~CC~C~A~TG~GCTTGGCTGGCTGCGTCcCCAGGCTGAGGTGGACCGATTTGTGGTGT~CTA~TCAGTGCCGAC~C~ 
74E: V I D G P O D L R V V S V T P T T L E L G W L R P O A E V D R F V V S Y V S A D N  
3433: A~GGGTGA~G~TGG~GT~C~TGAAA~GA~GGGA~GCTG~TGA~TGACCTGATGCCAG~GTAG~TATGTGGTGACTGTCACAGCG~GCGGGGCCGGGCAGTCAGCTACC~AGCTTCTGTCAGGG 
7 8 9 : 0 R V R L E V P P E T D G T L L T D L M P C V E Y V V T V T A E R G R A V S Y P A S V R  
3565: CC~CAG GTATGGCTGGCCA~GGTTAGGG~GGGCCCTGCTTTCCCAGCCTTCCATCC about 5kb 
033:A  N T qppr lqe l tv tdr tsds l l l rwtvpeqef  
3626: Thls ~ ino  acid se~enoe previously re.fred (30) .  CCATCCTGGCCGC~GTACAAATTTGTCCTGTATGGGTTTGTTGGC~G~GAGGCATG 
~65:ds fv iqykdrdgqpqvvpvegpqrsav l ts l  D P G R K Y K F V L Y G F V G K K R H 
3697: GTCCGCTGGTGGCTG~C~TCT GT~GT~AGCAGT~ACCcTGCC~TCTGTACT~TG~GAGGTTTTCTCAGTGCTTGGG~CCTGCTTTGG~TCC~GG~GGGTTC~T~GG~GT 
916:G P L V A E A K I 
3829: GGTG~TG~CTC~ATTCTG~GGGAAAGTAGTGGTGGGG~GGCAAAGAGTTTGAG~GCTCAGTGCAGCCT~GGG a~ut  ikb TGCCTCAGAGTGACCC~GTCCAG~ACTC~CCCCGC 
925: L P O S D P S P ' G T P P R  
3961: CTGGGA~ACCTGT~GGT~CAGAC~TACCC~TT~ACTG~CCTCTCCTG~CTGTCcCT~GGG~CAGTTT~CTTCATGGTCCAGTACAGGGAcAGGGATGGACGGCCCCAGGTGGTACCTGTG 
9 3 ~ : L G N L W V T D P T P D S L H L S W T V P E G O F D T F M V Q Y R D R D G R P O V V P V  
4093: GAAG~C~C~GCGTT~TTTGTTGTCTCCTCACTGGA~CCT~C~C~GTACA~TTCACT~TGTTTGG~TTGCG~C~C~GCGGTATGGcCCCCTCACGG~CGATGG~C~CTG a~ut  ikb 
9 9 2 : E G P E R S F V V S S L D P D H K Y R F T L F G I A N K K R Y G P L T A D G T T  
4225: CTC~GA~GGA~A~G~G~CCCCCCGCCCT~GTTCCTGGAGCA~CCCTCCTGGGGG~CTGA~GT~ACC~GCGT~CCCCAGACTCCTTGCGT~TCT~TG~CAGTGGC~CAGGGCCC 
1022: A P E R K E E P P R P E F L E O P L L G E L T V T G V T P D S L R L S W T V A Q G P  
4357: ~TT~CT~TTACTGGTCCAGTA~GGATGCA~GGGGCAG~C~GG~AGTG~CTGTTGCGGGG~T~G~TGAGGTTACTGTCC~CGGC~TC~ATCcCGACCGG~GTAT~GATG~TCTACGG 
1 0 6 4 : F D S F M V O Y K D A Q G O P O A V P V A G D E N E V T V P G L D P D R K Y K M N L Y G  
4409: GCTTCGAGGCAGGCA~GTGTG~GCCCGAGTCTGTGGTGGCCAAGACTG GT~GTCATGG~TG~CAGG~TCCCTCCccTG~TAG~CCcATCCTGTGAGCGGGA~TTGGCTGGGGcT~CTT~CTGCT~GGT 
ii05: L R G R 0 R V G P E S V V A K T 
4621: C~TCTT a~ut  1 .9~ GGGCCGT~TTCTTGCC~TTCTTTCCTC~TCTGCTATCCCAAAGTAGTCCCCCATGTAGCAGGTCACAGAAGG~CT~TTTCCCTTGTGCCAC~GTCTCCCC 
4753: ACTCCTAG~GCCT~AGCA~GACCT~CTGTAGGGGGCGGGTAG~GCCCACAGGGCTGTGATTCCAGAGCCAGCCACCC~GGACATGTCTCTCCTTGGAT~TTATGCCTCTATCTCTTCT~T~AGACT 
4585: CCTCAG~GGATGTGGACGAG ACCCCCAGCCCCACAG~CTGGCACG~GGC~CCGGAGTCCCCCGAGGAGCCGCTCCTGGGGGAG~TGACAGTGACA~TCCCcTGATTCGCTGAGCCTCTTCTGGA 
1124:  D P ~ P B R T G T E A P E S P E E P L L G E L T V T G S S P D S L S L F W  
5017: CCGT~GGG~GCTTC~CT~TTTCAC~GTG~AGTAC~G~CA~GGATGGGC~GCCCCGGGCGGTGCGTGTT~GGGC~GCAGAGTGAGGTCACCGTGGGAG~CCTAGAG~CCGGGCACAAGTACA 
I I 6 1 : T V P Q G S F D S F T V O Y K D R D G R P R A V R V G G K E S E V T V G G L E P G H K Y  
5149: A~TG~CCTGTACGGCCTC~C~GGGGCAGCGCGTGGGCCCGGTGTCCGCCGTGGGGCTGACAG T~GT~GGGG about 4kb GGCAGGC~TAGGG~TGATCT~GAGATG~TAT 
1 2 0 5 : K M H L Y G L H E G O R V G P V S A V G L T  
5251: GCCAGTGCAGGACTTGGATTTCACCCT~GT~GGTAGAAGCCACTGCGGG~CCAGCTCTGGCT~TGTGTT~CA~ a~ut  2.Skb CCCTGGAGCCACGCCTAGGGGAGCT~CAGT~C 
1227: A L E P R L G E L T V T  
5413: G~TAT~C~c~T~TCTGTGGGCCTCTCATG~cAGT~CCTGAGGGTC~TTcGACTCCTTTGTGGTTCAGTAC~GGACAC~GACGGGcAGCcCCAGGT~GTG~CGTGGCTG~AGATCAG~GGGAGGT 
1 2 3 0 : D I T P D S V G L S W T V P E G E F D S F V V O Y K D R D G O P O V V P V A A D O R E V  
5545: CACTATCCCTGACCTGG~ACCCTC~CCAAGTACAAGTTCCTGCT~TTTGF~G~TGGGAAAC~CGCAGCCCAGTCTCTGTGGAGGCAAAGACGG GT~TGG C CTACACAGCT~GCCTGAG 





6205: CGTGTGCTCCTGGGT~TA~GACCCAGTCTGT~G~GCTGCACCCTGCTGGGG~GCAGTCTGTGA~G~CGGAAAGAGGCTGGACAGAAAA a~ut  500 bp GCGATCCT 
1315: . . .A  I L 
Figure 2. Sequence of the XB gene. The approximate sizes of gaps in the nucleotide sequence are indicated. Because of the gaps, nucleotide 
numbers indicate only relative distances. BamI-II and EcoRI sites used in mapping the gene are underlined. Nucleotide ditferences in the 
2.7-kb cDNA (39), are shown as small letters above the gene sequence. Encoded amino acids are indicated below the second base of the 
corresponding codon, using the IUPAC single letter code. In exon 1 the signal peptide is separated from sequence of the mature protein 
by "/; cysteine residues that may participate in inter-chain polymerization are in bold, and hydrophobic amino acids of the heptad repeats 
are underlined. Amino acid sequence of repeat iii from Matsumoto et al. (30) is in small letters. Incomplete nucleotide sequences of repeats 
viii, xii, and xiii are indicated by ( . . . )  preceding or following known amino acid sequences. Potential sites for N-linked glycosylation 
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6337: CTC~TG~CGGTT~TG&GGC~GTT~GA~TCAAAN~GTGGTC~AGTTcAAGGACAAA~cGGCC~cAGGTGGTGC~GTGGAGGG~T~G~G~TCTGT~A~TGTcA~cccTcTGGATGC~GG~GC~ 
1 3 1 1 1 S N T V P E A S S T Q K V V Q F K D K D G P Q V V P V E G H E R S V T V T P L D A G R K  
6469z GTA~TTCCTCCTCTATGGCCTCCTGGG~AAGAAGCGC~TGGCCCT~TCACT~C~CGGCACCTCGGGT~GGGGCATT~CCTGCAGGTGACCAcCGTGACCCAG~cTCCGTGGGCCT~TCCTGGAc 
1 3 6 2 : Y R F L L Y G L L G K K R H G P L T A D G T S G E G H S L Q V T T V T Q N S V G L S W T  
6601: ~TCCCT~G~CCAGTTT~CTCCTTTGTGGTCCAGTACAAA~CAGGGACGGGCAGCCC~GGTGGTGCCCGTGGAGGGCAGCCT~GG~GGTCAGCGTGCCGGGCCTG~CCCTGCCCACAGGTAC~ 
1 4 0 G : V P E G Q F D S F V V Q Y K D R D G Q P Q V V P V E G S L R E V S V P G L D P A H R Y K  
6733: GCTGCT~TCTACGGGCTG~CCACGGC~GCGTGTGGGCCCCATCTCGGCCGTCGCCATTACTG GT~GTG CGGCAGCTGG~CACCTGTGCCTCCTTCCCGCCTGGCTCTCCTGGTCTGACTGAGCCA 
1 4 5 0 : L L L Y G L H H G K R V G P I S A V A I T  
6065: T~TCTCT~GCTTCC~TTTTAT~TATC~GTCCTTGTGCCCCTTTA~GT~GTTGCCCCAGTCC~GCCTcCAGCAAC~ACTGTCTGCTTTCGATCATCCTGGA~CAGCATTTTGACTCTCCATG 
G997: T~T~TCACAATAC~TCTCTTGTGTTTCATTTCTTGC~TTAGCACAATGCTTTTGARATTCACCCATGTG~GCAAAAGCTGGTCTTTCGATTGcTGAcTGCTTGCCCTCA~TCCCTCTCCT~C 
7129~ T~CTC~CCT~cAGT~TGGGTGCA~CA~C~GC~TCTGTCT~TACCTGTCTCTGTGAAc~AGCCGGCTGGGAAGAAACGGAAACTGAGAcCACGGCCC~CcCCTCC~ CGCCT~GCCCCACC 
1471: A P E P H 
7261: TCG~G~TT~GTG~GGAGGCCACGT~CACCCTGCATCTCTCCTG~TGGT~CT~GG~GAATTTGAcTCCTTCGAAATCCAGTACACAGATAGAGACGGGC~CTCCAAATGGTCCGC~AG 
1 4 7 6 : L G E L T V E E A T S H T L H L S W M V T E G E F D S F E I Q Y T D R D G Q L Q M V R I  
7393: ~GGTGAc~GGAAT~AT~CCCT~T~TGGCcTGGAATc~CCACA~TACCTGGTGACCCTGTATGGTTTCAGT~TGGG~GCATGTAGGTCCTGTC~TGTCGAGGcCCT~CAG GT~G~CTCTG 
1 5 2 0 : G G D R N D I T L S G L E S D H R Y L V T L Y G F S D G K H V G P V H V E A L T  
7525: C~ACTATG~CTCCTTTCA~TGGCTGG~GAGTCCA~GGACAGCAGAGTCCGCGGATACCTGCC~CCTcAGTCCTCTCTTTCCATGTCTCTGTC~AGTCcCGGAGGAGGAG~G~CTTcAG ~CCTCCC 
1560: E P P 
7657: ACCGCJ~CCCCC~GCCCCCCATCAAGCCTCGCCTGGGG~GcT~CCGT~CA~TGCCACCCCTGACTCCCTCAGCCTGTCCTGGA~GTTCCCGAGGGACAGTTTGACCACTTCCTGGTCCAGTACAGG 
1 5 6 3 : T A T P E P P I K P R L G E L T V T D A T P D S L S L S W T V P E G Q F D H F S V Q Y R  
7709: ~TG~TGGGCAGCCCJ~AGG~GTGAGGGGTCCAGGGCACGAGG~GGGGTCACCATCTCGGGCCTG~GCCA~CCATAAATAC~GATG~CCTGTACGGCTTCCAcGGTGGCCAGCGCATGGGCC~T 
I & O ? : N G D G Q P K A V R G P G H E E G V T I S G L E P D H K Y K M N L Y G F H G G Q R M G P  
7921: GTGTCTGTCGTCGGGGT~CAG GT~GTG~TGATGGGAGCCcCAGGGTGG~GCCATGG~GGGTcACCCTCTTGCTCACCCTCTTGCTCTTTGGT~TGACTGGTGGGG~TGGGAC~GGGTCTGGTCA 
1651: V S V V G V T 
8053: GCACCACA~CCTGCTTGTGGCTGGGGCTGGGGCTCCCCTTGGGCCTTCCTGTGAGGTT~CCACTGGCTCCTCCTGAA~GA~GGGGCCATCGGG~TTTTGCTGTGCTGGTGGCTGTCCCAGGTCCCCC 
0185: A~GCT~CCCTGG~cTTGT~TGTGTGTTAGCTGTcAGCTGAGCAGGAC~CCCAGCCCC~GAGTAGGCCTCTCTG~CT~CCTCGGTCCCCCAGTCATAGCCTTGGCTTCTCCCTCCTTTTcCCCAG 
1317: ATCCC~G~ATCCCc~GTCATAG~CTTGGCTTCTCCCTCCTTTTCCCAGATCCC~GGACATCCCCCTCACTCTCTCTTCCTCCTTCTCAG CTGCAGAGG~GAGACCCCCAGCCCCACAG~CCCAGC 
165$: A A E E E T P S P T E P S  
0449: ATGGAG~CCcG~GCC~G~T~GGAGCCGCT~CTGGGGGAGCT~CAGT~CCATcCT~CCCTGACTCGCT~GCCTCTCCTGGACCGTCCCCCAGGGCCGCTTC~CTCCTTCACCGTGCAGTAC~G 
1 6 7 1 : M E A P E P A E E P L L G E L T V T G S S P D S L S L S W T V P O G R F D S F T V Q Y K  
85%1: ~CAGG~CGGGCGGCCCCAGGTGGTGCGTGTTGGGGGC about 0.5kb CTTCCTCCTTTCTTTCTTTCTCTTTCTTTCTTTCTTTCACTTCTTTTCTTTCTTCGTGTTTAGAC~GGTCTCACTCT 
1 7 1 5 : D R D G R P Q V V R V G G . . .  
0713: AT~G~CT~G~TAGA~TCTGGCAcAGTCACAATTCAcTGCACTGCAGCCTC~CCTCCTGGGCTT~GG~c~ATccT~CCACTT~GCCTCCCG~TAGCTGG~CTAC~GTG~CTCCACCATGCCcAGC 
Ig45: T~TTTT~GTATTTTTTGTA~GGGTTAGCCATGTTGCC~GGCCAGTCTCG~CTCT about 1 kb ~TGTCTCAT~TTGTGTTCCCATTTGTTGCTG~TCAGGTCTATAG~GGAG 
$9?7: ~TA~TTcG~TTGAGAAAACTGAAATTTTAAATA~GT~T~GGGAAGGCCCACAGRAG~GGTGGCTTTTG~CAAA~CTTAAAG~GTGTGGGGAT~GCCATG~TATCTGGGGAAAGAA~AT 
9109: TTAGGTA~GGGAACAGT~TTGTAAAAGTACTGAGGTAG~GGCTGCCTGGCATGGTTGAGGGACCAT~GG~G~CACAAAATCTGATTATGATTAT~TCAGAAATCGATCTT~GTTAGGGCCA~CT 
9241: GGGCCCACCTTCTGACCT~GACAGCTGGGGCCTC~CACCTCCTTG~GC~GAGAAAAGATTCTGTTTCTATCTCTTC~TAG GGCC G~GAGGAGTCCCCTGATGCTCCTCTTGCRAAGCTGC 
1728: P E E E S P D A P L A K L  
93?3: G~CTAGGG~TGA~GT~GA~T~CCTCC~CTCCCTCAGCCTCTCCTG~cAGTCCCC~GGGCCAGTTT~CCATTTCTTGGTCCAGTTT~G~TGGGGACGGGCAGCCC~GGCGTTGCGGG 
I ? 4 1 : R L G G M T V R D I T S D S L S L S W T V P E G Q F D H F L V Q F K N G D G Q P K A L R  
9505: TGCC~CAC~G~TGGG about 3.2 kb GGACCCTGCCATCCTCTCTGTGTCCCTTTTTCTCCAG CTGCAGAGGAAGAGACCCCCAGCCCCACAG~CCCAGCATGGAGGCCCCG~GCCCCC 
1785:VPGHEDG. . .  A E E E T P S P T E P S M E A P E P P  
9637: TGAG~GCCGCTCCT~G~GAGCT~CAGT~CAF~C~1LT~TCCCCTGACTCGCTGAGCCTCTCCTGGACCGTCCCCCAGGGCCGCTTCGACTCCTTCACCGTGCAGTAC~GGACAGGGACGGGCGGCCCCA 
I $ 1 1 : E E P L L G E L T V T G S S P D S L S L S W T V P Q G R F D S F T V Q Y K D R D G R P Q  
9769: ~TGGTG~GTGTTGGGGGC~G~GAGC~GGTCACC~TGGGGGGCCTGGAGCCTGGGCGcAAATACTTGATGCACCTGTATGGC~TCCACGAGGGGCGGCGCCTGGGc~cCGTGTCAGCCGTGGGcGTGAC 
I $ 5 5 : V V R V G G E E S E V T V G G L E P G R K Y L M H L Y G L H E G R R V G P V S A V G V T  












11485: TATCCCCCTATATTACCTTTCAGCCC~C~GA~ATGTG~CGAGACCCCCAGCCCTACAG ~CCAG CACAGAGGCCCCA~GCCCCCCGAGGAGCCTCTCCTGGGGGAGCTGACAGTGAC~TC 
1899: E P G T E A P E P P E E P L L G E L T V T G S S  
11617: cC~T~CTCGCT~GCCTTTcCTGGAcCGTcCCCCAGGGCCGCTTTGACTCCTTCACCGTGCAGTAC~G~CAGGGACGGGCGGCCCCAGGCGGTGCGTGTTGGGGGCCAGGAGAGC~GGTCACTGTGAG 
1 9 2 3 : P D S L S L S W T V P Q G R F D S F T V Q Y K D R D G R P Q A V R V G G O E S K V T V R  
11749: GGGCCTGGAGCCTG~CGC~GTAC~GATGCA~CTGT~CGGCCTCCACGAGGGGCGGCGCCTGGGCCCGGTGTCTGCCGTGGGCGTCACAG GTGA TGAGTGTG GTGGGGCAGGGTTGG~GACAGCCCT 









12937: GGGGCCAG~CCTCACTGTCCC~CACGTGTCTGTCC~CTCCAG AG~T AAGC~CCA~CC~GCAGTGCCTACCATGACCCCTGAGCCCCCCATC~GCCTcGCCTGGGG~GCT~CCATGACAG 
1997: E D E A E T T Q A V P T M T P E P P I K P R L G E L T M T  
13069: ATGCCAC~C~T~CTCCCT~GCCTGTCCTGGACGGTTCCC~GGGCCAGTTTGACCACTTC~TGGTCCAGTACAGGAATGGGGATGGGCAGCCC~GGCGGCGCGGGTGCCGGGGCAC~GGACGGGGTCA 
2 0 2 6 : D A T P D S L S L S W T V P E G Q F D H F L V ~ Y R N G D G Q P K A A R V P G H E D G V  
13201: CCATCT~GGCCTG~GCCAGA~TAAATAC~GATGAACCTGTACGGCTTCCACGGTGGC~GCGCGTGGGCCCCATCTCTGTCATTGGGGTCACGG GT AGT GATGATGGCAGCCCCAGGGTCGGAGC 
2 0 7 0 : T I S G L E P D H K Y K M N L Y G F H G G O R V G P I S V I G V T  
13333: CGTGGGAG~TCACCCTCTTGCTCTTTGGT~T~CTGGTGGGG~TGGGCCAG~GTCCGGTCAGCA~cACAGACCTGCTTGTGGGCTGGGGCTCCcCTTGGGcCTTCCTCTGAGGCT~CCCCTGGCTCC 
134~5: TCCT~G~AGG~GGGGC~TC~GAGTTCTG~TGTG~TGGTGACTGTCCCAGGTCCCCCACAGCT~CCCT~CTTGTCATGTGTGTTAGCTGTCAGTTGAGCAGGACCACCCAGCCCC~GAATGGGC 
13597: TTTTCTGAAAT~CCTCA~TACCCAGTAGTGGCCATGGTTTCTCCCTCCTTCCCTTG~GACCT~GCA~TCCCCcAGGCACCTGGCATCCTCTCTATATCTCCTTTTCTCAGCTGCAG AGG~GAGAC  
2103: E E E T 
13729: CCCA~CC~CGGAACT~ACTGAGGCCCCG~GCCCCCTGAGG~GCCGCTCCTGGGGGAGCT~CAGTGA~GGATccTCCccTGACTCGCTGAG~CTCTCCTG~CCATCCCCCAGGGCcACTTCGAC 
2 1 0 7 : P S P T E L S T E A P E P P E E P L L G E L T V T G S S P D S L S L S W T I P Q G H F D  
13561: TCCTTCACCGTG~GTACAAG~cAGGGACGGGCGGCCCCAGGT~TGCGTGTCAGGGGCGAGGAGAGGCAGGTCACcGTGGGGGGCCTGGAGCCCGGGCGCAAATAC~GATGCACCTGTACGGCCTCCAC 
2 1 5 1 : S F T V ~ Y K D R D G R p Q V M R V R G E E R Q V T V G G L E P G R K Y K M H L Y G L H  
Figure 2. 
a~ circled. The polyadenylation signal of TN-X is boxed, and ~at  of P450c21B is indicated by a dashed overlin¢. EMBL accession numbe~ 
am as ~l lows:  X71923 = exons 1 and 2; X71924 = intmn 2; X71926 = Fn ~peat  i; X71925 = Fn ~peat  iii; X71927 = Fn ~peat  
iv; X71930 = Fn ~peat  v; X71938 = Fn ~peat  vi; X71928 = intmn 9; X71929 = Fn ~peat  vii; X71931 = intmn 10; X71936 = Fn 
~pea~ vii i-xii; X71936 = Fn ~pea~ v i i i -~ i ;  X71932 = intmn 14; X71934 = Fn ~peat  ~i i ;  X71935 = Fn ~peat  xiv; X71933 = Fn 
~pea~ xv-xvi i ;  X71937 = Fn ~pea~ xvi i i -xxix; fibfinogen domain, 3' un~anslated ~gion.  
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13993: GAGGG~GGCGTGTGGGCCCGGTGTCCACCGTGGGTGT~CAG GTGAGTGTTTGTGAGTGAGG~GATGG~CCTAG~GATGTTGCTTTCTCTGC~CTTCATG~t~ACAAAAATATTCTCACCAGCCGGGC 





14653: GCTTTAG~GAGAATTGT~GGRACTGGCTTGTGTTTGGTGTTTA~GACTTAGA~GCTTCTCTTATAGACC a~ut 800 ~ ~GGCCGCAG~GAGGA~G~TGAAGAGCTGTGCTGGAG 
14755: G~GTGTGGGCAGCATCGTCCTGCTCTTGGGCACTTTGTGTTTTGT~CACATCCTTTCTATGCTG~CTGAGAA~CCAGGGACCTCACTCTCCCTATATGTGT~TGTCCAGCTCCAG AG A G~ CAGAGA 
2209~ E D E A E 
14917: CCACCCAA~GTG~C~A~C&~c~C~T~G~CC~CC~CAAGCCTAGCCT~GGGGAGCTGACcGTGACAG~TG~CACCCCTGACTCCCTCAGCCTGTCCTG~T~GTCCG&GGC~AGTTT~CACTTCC 
2 2 1 4 : T T Q A V P T T T P E P P N K P S L G E L T V T D A T P D S L S L S W M V R G Q F D H F  
15049: TGGT~CAGTACAGGAATGGG~TGGGCAGCCc~GGTGGTGCGGTGGCC~GGGCACGAGGACGGGGTCACCATCTCAGGCCTGGAGCCA~CCAC~GTAC~TG~CCTGTACGGCTTCCACGGTGGCC 
2 2 5 8 : L V Q Y R N G D G Q P K V V R W P G H E D G V T I S G L E P D H K Y K M N L Y G F H G G  
15181: AGCGCGTGGGCCCCATCTCTGT~TTGGGGT~CAG GTGAGTGTACGATGG~CGCA~GTGGGGCCTGTGG~GGGTCTCCCTTTCTCTGGTGATGGGTG~CTGGCCCAGG~GCCCCTCTGCTCTTGG 
2 3 0 2 : O R V G P I S V I G V T  
15313: CT~G~ATGGTACTTTTTTGTCTTTCC~CACTTCC~T~G~CTGACAGATCTTCCTGGGTG~GGGCCCTGT~GCTCTGTTG~TGGCTGTCCC~GTTCCCCAGCACTGACCTCAGAGCTTGTCAT 
15445: GTGTGTTGA~TGTAAACTGAG~c~CC~GcTCCAAA~TCGGCCTCTcC~GCTGAcCCCAGACCCCCACTCATGGcCACCA~TTC~CTCTCCTTCCTCAC~GAC~C~GGACATCC~CCAGGG~ 
15577: GCTGCCTCACCTTCTCTGTCCCCTCTTCTCAG CTGCAGAGG~GAAACTCCCGCCCCCACAG~CCCAGcACG~GGCCCCGGAGCCCCCTGAGGAGCCGCTCCTGGGG~GCTGAcAGTGA~AF~C~TC 
2314: A A E E E T P A P T E P S T E A P E P P E E P L L G E L T V T G $ 5  
15709: CC~T~CTCGCT~GCCT~TC~TG~CCATCCCCCAGGGCCGCTTC~CTCCTTCACTGTGCAGTAC~GGACAGGGACGGGCGGCCCCAGGTGGTGCGTGTCAGGGGCGAGGAGAGCGAG~TcA~TGGG 
2348:PDSLSLSWTIPQGRFDSFTVQYKDRDGRPQVVRVRGEESEVTVG 
15841: GGGCCTGGAGCCCGGGC~AAATAC~TG~ACCTGT~CGGCCTC~CGAGGGGCAGCGCGTGG~CCCAGTGT~CGCTGTGGGTGTGACAG GT~ T~GTGTGAGTGAGGC~GGTGGGG~GATGGCCC 


















I%217: CACATCCTTTCTATGCTGAACT~GAACCCAGGRCCTCACTCTCCCACACGTGTCTGTCCAG TCCAGAGGATG~GCAGAGACCACCC~GCAGTGCCCACCAC~CCCCTGAGCCCCCC~C~GCCTCG 
2422: A P E D E A E T T Q A V P T T T P E P P N K P R  
18349: CC~CGGGGAGCT~CCGTGA~TGC~CCCT~CTCCCT~GCCTGTCCTGGATGGTCCCCGAGGGCCAGTTTGACCACTTCCTGGTCCAGTACAGG~TGGGGATGGGCAGCCC~GGTGGTG~GGTG 
2 4 4 6 : L G E L T V T D A T P D S L S L S W M V P E G Q F D H F L V Q Y R N G D G Q P K V V R W  
18451: G~GGG~CACGAG~GGGGTCA~CATcTCAGGCCTG~GCCAGACCACAAGTAC~GATG~CCTGTACGGCTTCCACGGTGGCCAGCGCGTAGGCCCTGTGTCTG~ATTGGGGTGTCGG GT~GT ~T 




19009: CAG AGGAA~C~C~G~C~ACAGAACCCAGCACTGAGG~CCCGGAGGCCCCTGAGGAGCcGCTCCTGGGGGAGTTGACAGTGACAFa~TCC~CT~CTCGCTGA~CCTCTCCTGGAC~GTCCCCC 
2530: E E E T P S P T E P S T E A P E A P E E P L L G E L T V T G S S P D S L S L S W T V P  
19141: AGGGCCGCTT~CTC~TTCACCGTGCAGTACAAG~CAGG~CGGGCAGCcCCAGGTGGTG~GTGTCA~GGGCGAGGAGAGCGAG~TCACCGTGGGGGGCCTG~GCCCGGGCGCAAATAC~TGCATC 
2573:QGRFDSFTVQYKDRDGQPQVVRVRGEESEVTVGGLEPGRKYKMH 
19273: TGTACGGCCTCCACGAGGGG~GCGCGTGGGCCCAGTGTCCACCGTGGGCATCACGG GTGAGTGGGGGGACAGGCCCTCGTCCCCAGGTTTACCTCTGCAGCCCCCTTGTGTTTCTCCTTTGGATCTTGGCA 





19933: TCTTTTCAG C~CCCTGCC~A~CCACTG~CGGTGGAGCCCCGCCTGGGGGAGCTGGCGGTGGAGGCC~TGACCTCGGACTCAGTG~CCTCTCATGGACGGTGGCCCAGGGCCCCTTTGACTCCTTCCTGG 
2636: A P L P T P L P V E P R L G E L A V E A V T S D S V C L S W T V A Q G P F D S F L  
20065: TA~AGTACAGG~CGCGC~GGGGCAGCCCC~GGCAGTGCCTGTGAGCGGAGACCTCCGAGCGGTAGCCGTCTCGGGGCTGGTACCGGCCCGC~GTAC~GTTC~TGCTCTTTGGACTCC~GAATGGGAAAC 
2 G 7 7 : V O Y R D A O G Q P Q A V P V S G D L R A V A V S G L V P A R K Y K F L L F G L ~ N G K  
20197: GCCACGGCCCAGTCCCTGTG~GGCCAGGACCG GTGAGT~GGGCTGGAGGCCTCCCGCGGcCAGAGCCTTCGCCCCCTTGTGGCACCTGTTGG~TTTCAcGTTCTGTGCC~CACACTCCAGTCCTCAGC~ 
2721:R  H G P V P V E A R T 
20329: CCCACT~TTTATTGGGTC~GGAA~CCCAGGCCCT~GCTCTCCTCTCCCACTCAcACTCATCCcTCT~CCTACTTTcCCTGCACCCCAGGGGACACTTGcTTTCTTGTCTGGCTCCTCTTTTATT~CTA 
20461: CTCCTGGCC~GTCACCCTCCCGTTCCTGG~CCGG~TCA~GCCATAG~GCCcAGGAAGCTC~GTGGCCCCTTTGCCTCCATCCCACTCTCCATGCACcTC~CTGTCTTTTcCAG CCC ~ACA C~ 
2732: A P D T K 
20593: ACCGT~TCCCCGC~T~CTC&CTGT~CA~T~GACCC~T~CTCCGTGCGCcTCTCGTGGACGGTCCCTGAG~GcCAAT?c~A~TCCTTCGTG~TCCA~TAC~GGAT~GGAT~GTCGGCTCCA 
2 7 3 7 : P S P R L G E L T V T D A T P D S V G L $ W T V P E G E F D S F V V O Y K D K D G R L O  
20725: GGTGG~CC~TG~A~C~C~GCGGGAGGTCACAGTCCAGGCCCTG~GCCCAGTAGGAAATACAGGTTCCTGCTCTATGGTCTGTCAGGCAGGAAACGACTGGGCCCCATCTCTGCTGACAGCACCAC 
2781:VVPVAANOREVTVOALEPSRKYRFLLYGLSGRKRLGPISADSTT 









22045: ~TTT~G~C~T~A~T~GG~GGCTG~AGGG~TTAGC~A~AGG~&GCATGTGA~T~GCTTTCc~TCCTCcCTCTGCACAG CTC C TCCAG~GGAGCTACCTCCCCACCTGGGGC.AACT 
2825: A P L E K E L P P H L G E L  
22177: GACCGTGGCTGAG~CCTCCAGCTCTCTGCGCCTGTCCTGG~C~GTAGcCCAGGGCCCCTTT~CTCCTTCGTGGTCCAGTACAGG~ACACGGACGGGCAGCCCAGGGC~GTGCCTGTGGCCGCAGACC A 
2 B 3 9 : T V A E E T S S S L R L S W T V A Q G P F D S F V V Q Y R D T D G Q P R A V P V A A D Q  
22309: GCG~A~GT~CCGTA~G~CCTGGAGCCTGGC~GAAATACAAGTTTCTGCTCT~CGGGCTCCTTGGGGGA~GCGCCTGGGCCCG~TCTCTGCCCTGGG~TGACAG GTGA CTGCTGT CCTGGCTA 
2 $ $ 3 : R T V T V E D L E P G K K Y K F L L Y G L L G G K R L G P V S A L G M T  
Figure 2. 







23233: GCCCCTCACT~T~CTCCCCTGGGCTTCTCCCACGCAG ~AGAAGAG~CAC~RGC~CACAGTT~G~k~GG~C~TGAG~TG~GAG~CCCG~cTAGGAG~GCT~C~GT~C~C 
2919: A P E E D T P A P E L A P E A P E P P E E P R L G V L T V T D  
23365: ACAACCCC~ACTCCATGCCCCTCT~GTGGAGCGTGG~C~A~GCCCCTTTGATTCCTTCGTGGTCCAGTATG~G~CG~CGGCCAGCCCCAGGCCTT~TCG~GGCGACCAGAGC~GATCCTC 
2 9 5 0 : T T P D S M R L S W S V A Q G P F D S F V V ~ Y E D T N G Q P O A L L V D G D O S K I L  
2349~: KTCT~GG~CTG~GCCCkGCACCC~CTACkGGTTC~TC~TCTATGGCCTCC~GGAAGCGC~TGGGGCCC~TCTCAGCT~CGGCACCACA~ GTAC AC GGCGTCTCCGG~CTCTkGCCTAGGAC 
2 9 9 4 : I S G L E ~ S T P Y R F L ~ Y G L H E G K R L G p L S A E G T T  
23~29: ~GAAGG~GAAACGGGGGCTCAG~GGGGTGGTCG~GGGAAAGAGCGT~GGCGGGTACCAGG~G~TG~TGGGCTG~TGC~GTG~CCTTTAGCTCTGCCCCACAGGACCCCCCTGTGGCT 
23761: GCAAGTCCCTGGTTACA~TA~GAAA~GGGCAGG~G~GGGTGG~AGG~CGTG~TCTGGGTCACCAAGCTGGTGTGCTTCTGTCTCC~TCCCTTCTCCCCCACCCACTCCGTGCAG GGCTGGCTCC 
302~: G L A P 
23593: TGCTGGTCAGAC~TCAGAGCAGTC~G~CCCCGCCTGTCC~GCTGTCTGT~CT~CGTGACCACCAGTTCACTGA~GCTC~CTGGGAGGCCCCACCGGGGGCCTTCGACTCCTTCCTGCTCCGCTTTGG 
3 0 3 0 : K G O T S E E S R P R L S Q L S V T D V T T S S L R L N W E A P P G A F D S F L L R F G  
24025: CGTTCCATCACCAAG~TG~GCCGCAT~GCGTCC~CTGCTGCAGCGC~GCTG~TGGTGCC~CG~CGCGGCACTCGGCCGTGCTCCGGGACCTG~GTTCCGG~CTCTGTACAGcCTGACACTGTA 
3 0 ? 4 : V P S p S T L E P H P R P L L Q R E L M V P G T R H S A V L R ~ L R S G T L Y S L T L Y  
24157: TGGGCTGC~G~CCCCAC~GGCC~CAG~TCCAGGG~CCGCCCGCACCCT~GCC~G GT~GGACCCACACACACTCTGCCCCA~AGTGGGGGTCTTTGTACTTCACGGGGGGGACCTAGTGCCT~ 
3 1 1 8 : G L R G P H K A D S I Q G T A R T L S P  
242~9: ~CCAGCGGTG~G~T~G~GTTGGTGGTGG~CCT~GGAAT~TG~CAGCGACTTCCATTCCT~GGACTAGAGGAAAAGGGGTGGT~GCcTGTGCTGGAG~AGAGGCGAG~GGGG~CT~GcAG~GA 
24421: C~GCCTCCCTGCCCCTGCCTGCGTCATTGTTCCTTGACCCCTCTGCAC TTCTGGAGAGCCCCCGTCACCTCC~TTCAGTCAAATCACG~GACCTCAGCC~GGTC~CTGGATCCCCCCACCATCCCGG 
3135: V L E S P R D L Q F S E I R E T S A K V N W M P P P S R  
24553: GCG~GCTTC~GTCTCCTACCAGCTGGCG~CGGAG GTGGTGCCTTTGCCATGTGCTCATCCCCTC~CATTTCCTCTCCCCCCTGCACT~TGCCCACCCTCCAGCT~CCCTG~GGTTCCCT~GGT~C 
3 1 £ 6 : A D S F K V S Y ~ L A D G  
246~5: CCTC~TCCCC~TGTTTTCAG G~GCCTCA~GTGTGCAGGTG~TGGCCAGGCCCGG~CC~GAA~CTCCAGGGGCTGATCC~GGCGCTCGCTATG~GGTGACCGTGGTCTCGGTCC~GGCTTTGAG 
3179: G E P ~ S V Q V D G O A R T Q K L Q G L I P G A R Y E V T V V S V R G F E  
24%17: ~GAGTGAGCCTCTCACAGCCTTCCT~ACGG TGA~TG~CTGGGACC~GGGGC~GAGGTGG~GCC~GAAAACG~CATGGGTGGGAGTTGAGA~G~CG~GGAGGGTGAA~GGGAGGTGGTG~ 
3 2 1 6 : E S E P L T G F L T T  
24949: GG~TCCGATTGCGGA~GG~GGC~AGTG~GTCTGGGGAGGCACGGAGTAGAGAGAGCCGCGGGG~CCCcTCTGAGCCCCTCCCCTTCCCCCAG TTCCTGA GGTCCCACACAGTTGCGTGCACTG~CTTG 
3227: q V P D G P T Q L R A L ( ~ L  
25081: ACC~GG~TTCGCCGTGCTGCACTGG~GCCCCCCCAG~TCCTGTAGACACCTATGACATCCAGGTCACAGCCCCTGGGG GTGA CAGGGCTGAGGCCTCTGGRGGGGACTTGTTCAGGGTGGGGATTGC 
3 2 4 0 : T E G F A V L H W K P P O N P V D T Y D I O V T A P G  
25213: AGGGGGGAGGCTGGACTCTGGCCGAG~TGGACGGGGGAGGCCTTGATGCCCCTCTCTA~CTCCCAG C C G CTCTGCAGGCG~GACCCCACGCAGCGCGGTGGACTACCCCCTGCATGACCTTGTCCT 
3267: A P P L G A E T P C S A V D Y P L H D L V L  
25345: CCACACC~CTACACCGCCACAGTGCGTGGCCTGCGGGGCCCC~CCTCACTTCCCCAGCCAGCATCACCTTCACCACAG GTAGG TCTGTGGGCTGTGTGGGACAGGGAGAGGAGGTAGAGGGAGCCAGGT 
3 2 ~ 9 : H T ( ~ Y T A T V R G L R G P ~ L T S P ~ S I T F T T  
25477: TGGGCCTCATCCCCRTCTCCTCTTCCTGCTTTCCCTCCTAG G ~TAGAGGCCCCTCGGGACTTGGA~GCC~GG~GTGACCCCCCGCACCGCCCTGCTCACTTGGACTGAGCCCCCAGTCCGGCCCGCAGG 
3 3 1 5 ~  G L E A P R D L E A K E V T P R T A L L T W T E P P V R p A G  
25609: CTACCTGCTCAGCTTCCACACCCCTGGTG~CAG~CCAG GT CCCCGGCCCCACTGACCC~CTCCCCTcCCTGGGTGATTCCAC~GGTGCTCCTCTGGCcCTCCCGGAGGGTCTCCACCTCCCTCTCCC 
3346: Y L L $ F H T P G G 0 N ~ ~gq 
25741: CTGACCCCCCCTTGTCTGTCCCACAGGAG TCCTG~TCCCAGGAGGGATCACATCTCACCAGCTCcTTGG~TCTTTCCCTCC~CCTCCTAC~TGC~CGGCTCC~GGCCATGTGGGGCCAGAGCCTCCTGC 
3359: I L L P G G I T S H Q L L G L F P S T S Y N A R L Q ~ M W G O S L L  
25873: CGCCCGTGTCCACCTCTTTCRCCACGG TACCT~CGCAcGGGCCCGGGGCCGG~GGCTGGGTGGGCAGCCAGGGCCT~GGCTTGGA~GGACTGGCCCCTGCTCTCCTCTCCCAG GTGGGCTG GC-A~C 
3393:P  P V S T S r T T G G L R I 
26005: ~CCTT~CCAGG~CTGCGGG~GGA~TGCAGAAcG~GCCGGTGCCTCCAGGACCAGCACCATCTTCCTC~CGGC~CCGc~GCGGCCcCTC~CGTGTTTTGCGACATGGAGA~TGATGGGGGCGGC 
3 4 0 7 : p F P R D C G E E M O N ~ A G A S R T S T I F L N G N R E R P L N V F C D M E T D G G G  
26137: TGGCTG GTGGG~G~TTCCC~GG~GTCTGTGCRGGGC~GGGGCTGTTGGCCCCGGAGCCAGAGGCTG~TGGTGCCCCCACTTGCTTCCCAG CTGTT CAG GCCGCATGGATGGACAGACAGACTTCTGG 
3~51:WL V F Q R R M D G O T D F W  
26269: AGG~CTGGGAG~CTATGCCCATGGTTTTGGGAACATCTCTG~GAGTTCTGGCTGG TCAGTGCCTCACAGGGACTGGGG~GTACGGATGGGGATGGGGGCCCTGTGGACACCAGGACCCTGAT~GGC 
W E D Y A H G F G ~ I $ G E F W L 34~6: R D 
26401: CACGTATCCCACCCCCAG C~TG~GG~CCT~CACAGCCTGACACAGGCAGGT~CTACTCCATCCGcGTGGACCTGCGGGCTGG~GACGAGGCTGTGTTCGCCCAGTACGACTCCTTCcACGTAGACTCGG 
3485: G N E A L H S L T Q A G D Y $ 1 R V D L R A G D E A V F A O Y D S F H V D $  
26533: CTGCG~GTACTACCGCCTCCACTTGGAGGGCTACCACCGCACCGCAG GT~GCAGAGGCTGTGAG~CTGGGAGGGTCAGGCTGGCAGGG~GGCCCCTCATGGCTCCTTCCTCCACCCTGCCCAG GGGA T 
3 5 2 3 | A A E Y Y R L H L E G Y H G T A  GD 
26665: CCAT~GCTAC~CAGCGG~GTGTCTTCTCTGCCCGT~ATCGGG~CCCC~CAGCTTGCTCATCTCCTGCGCTGTCTCCTACCGAGGGGCCTGGTGGTACAGG~CTGCCACTACGCC~CCTC~CGGGC 
3 5 4 1 : S M S Y H S G S V F S A R D R D ~ N S L L I S C A V S Y R G A W W Y R N C H Y A N L N G  
26797: TCTACGG~GCACAGTG~CCATCAG GT~GGGGTGGCGAGGCGGCTCAGAGCT~GGGTGG~TGGGGCTCGGCCTGCCTAGGTTTCAGCCCCACAGTGT~CAGGC~GGGAcT~GTGGCTGGGTGAAATG 
35~5:L  Y O S T V D H O 
26929: GAAC~AT~ATGc~GcCTCG~AGAGG~G~TG~GTTGATTTATTGGCTGGAA~GGGCCAG~TCAG~TT~GCCTC~TCCTCTGCAGCGGAGGGTCAGG~GG~AGCTCTGCGGGGAGGTTGGTT~GTG 
2~061: CTGG~GCTACCTCCTT~GGGGRATGGGAAGAGCAGATGG~CATCCGGCTTTGACTCTCTCTTGAC~CCCCTT~CCCAG G~T~GCTGGTACCACTGG~GGGCTTCGAGTTCTCGGTGCCCTTCAC 
3594: C V $ W Y H W K G P E F S V p F T 
2~193: GGAAATG~GCT~CCAAGAAACTTTCGCTCCCCAGCGGGGGGAGGCT~GCTGCTGCCCACCTCTCTCGCAC~CCAGTATGACTGCCGAGCACTGAGGGGTCG~CCCGAGAG~GCCAGGGTCCTTC 
3 6 1 1 : E M K L R P R N F R S P A G G G 8  
273251 ~CCACCCAGCCGCTG~GGAAGCCTTCTCTGC~C~TCTC~CAGCkCTGTGTTTACAGGGGGGAGGGGAGGGGTTC~TACA~G~AGAAACTGAGGTACCC~A 
Ngure 2. 
vealed two additional exons encoding 100 amino acid repeats 
(xxi and xxii in Fig. 1) similar to those found in the 5' end 
of the X cDNA. Genomie DNA lying 5' of that in XXB-1 was 
obtained by identifying an overlapping phage (XXB-2) from 
a library in XCharon 4A by hybridization to a 1.4-kb BglII 
fragment (bases 19,651-21,088 in Fig. 2) from the 5' end of 
XXB-I. This extended the available DNA another 10 kb. 
Complete sequencing of this DNA (Fig. 2) identified repeats 
xv-xx (Fig. 1). When this proved insufficient, three overlap- 
ping X-B cosmids (cTNX: 2-1, 6-2, and 1A in Fig. 1) were 
identified extending 60 kb from the 3' end of P450c21B. 
Probing of restriction digests of these cosmids with a geno- 
mic probe spanning repeats xvi and xvii identified multiple 
bands, suggesting that additional repeats remained to be 
identified. Restriction endonuclease mapping of upstream 
DNA was followed by subcloning of overlapping BamHI and 
EcoRI fragments. The ends of each subclone were sequenced, 
and the fragments were ordered by further mapping and 
sequencing. Repeats i, iii, v-vii, and xii-xiv contained, 
or were very near BamHI or EcoRI sites, and each was 
identified by sequence homology tO repeats xv-xxix. An- 
other four repeats (viii-xi) were identified by additional se- 
quencing ofa 3-kb BamHI fragment, which showed particu- 
larly intense hybridization to the genomic probe containing 
repeats xvi and xvii. Repeat iv was identified by RT/PCR. 
Repeat ii was mapped but not sequenced (31), and has not 
been verified by us. Each repeat had canonical splice junc- 
tion sites at its boundaries, and maintained the same open 
reading frame as the original 2.7-kb cDNA. 
We searched for EGF-like repeats similar to those found 
near the amino terminus of tenascin by using a PCR- 
amplified probe encompassing 1.1 kb of the EGF domain of 
Bristow ot al, Tenascin-X 271 
human tenascin. However, low-stringency h bridization de- 
tected no such sequences in cosmids cTNX: 1A, 6-2, or 2-1. 
Based on the partial sequence of a recently reported genomic 
DNA fragment of TN-X (31), we synthesized PCR primers 
corresponding to the apparent EGF-like domain (bases 903- 
922) and the apparent upstream heptad domain of TN-X 
(bases 250-269). These primers amplified a 327-bp frag- 
ment from adrenal eDNA and a 673-bp fragment from 
genomic DNA. This 327-bp 5' eDNA was then used to iden- 
tify our final cosmid cTNX-5 (Fig. 1). 
To identify additional upstream coding regions, we used 
the RACE procedure (12) using oligonucleotide s quences 
within the 327-bp 5' eDNA fragment. Complementary DNA 
was synthesized from adrenal or muscle RNA using an oligo- 
nucleotide primer in the EGF domain (bases 831-850). This 
eDNA was 3' tailed with dC, PCR amplified with poly(dG) 
linked to the adaptor primer and a second oligonucleotide 
in the EGF repeat (bases 806-826) (the 3' primer). A second 
round of PCR was performed with the adaptor primer and 
an oligonucleotide in the heptad repeats (bases 263-282 in 
Fig. 2). The final product was cloned, and colonies were 
screened with the 327-bp 5' eDNA. The sequences of posi- 
tively hybridizing clones xtended 220 bp into and beyond 
a region reported as the 5'-most intron by Matsumoto et al. 
(31), indicating that his was actually an exonic sequence. To 
demonstrate that his sequence was actually part of an exon, 
we performed an additional RT/PCR experiment (Fig. 3). 
PCR amplification offetal muscle DNA using specific pri- 
mers (bases 60--80 and 806-826 in Fig. 2) yielded a419-bp 
fragment, but PCR amplification offetal muscle RNA with- 
out reverse transcription yielded no product, demonstrating 
that the PCR product arose from newly transcribed eDNA 
and not from contaminating eDNA or genomic DNA. Am- 
plification of genomic DNA or of cosmid cTNX-5 yielded a 
765-bp product, differing from the 419-bp RT/PCR product 
by retention of the 346 bp in intron 1. Inclusion of this new 
DNA in exon 1 was also verified in fetal adrenal RNA by 
RNase protection assay (data not shown). 
Determination f the correct intron/exon organization pro- 
vides the sequence of the amino-terminus, including two 
ATG translational initiation c dons, immediately preceded 
by a TGA stop codon. The algorithm of von Heijne (55) 
strongly predicted that the first 22 amino acids constitute a 
leader peptide for the secretory pathway, consistent with the 
hypothesis that TN-X is a secreted protein of the extracellu- 
lar matrix. We mapped and sequenced a total of 37 exons 
encoding 3,626 amino acids of the XB gene (Fig. 2). In addi- 
tion, Fig. 1 shows Fn llI repeat ii, encoded by exons 4 and 
5; this was mapped by Matsumoto et al. (30), but the se- 
quence was not reported. Sequencing of three additional Fn 
m repeats i  incomplete, although the lengths of missing se- 
quences can be estimated from Fig. 4 A. Thus we estimate 
that the complete TN-X gene contains 39 exons encoding a
protein of about 3,816 amino acids. Because fairly large 
regions of the gene remain unsequenced, additional exons 
encoding Fn Ill repeats may remain undiscovered. 
Structural Features of the XB gene and Encoded 
TN-X Protein 
The organization fthe 39 exons of the XB gene is very simi- 
lar to that of tenascin. Exon 1 contains a small amount of 
5'-untranslated sequence a d ncodes the signal sequence 
Figure 3. Exon/intron organization of the 5' end ofthe XB gene. 
(Top) PCR using a 5' primer in the signal peptide and a 3' primer 
in the EGF repeats. (Markers) Bacteriophage PM-2 cut with Hind- 
III. Other lanes are PCR products obtained with the following tem- 
plates: human genomic DNA, cosmid cTNX:5 DNA, random- 
primed human fetal muscle eDNA, muscle RNA without reverse 
transcription (R'/), and without added nucleic acid. (Bottom) Auto- 
radiogram of the gel pictured above, probed with a 327-bp robe 
from the heptad domain (see text). 
and the "head piece 7 which in tenascin and restrictin is 
responsible for polymerization of the protein monomers into 
multi-armed "brachion" structures. The carboxy-terminal 
half of the head group is similar in TN-X and tenascin, and 
contains three heptad repeats flanked by five conserved cys- 
teine residues, suggesting that TN-X is also capable of form- 
ing multimers, as described for tenascin (52). Sequences up- 
stream from these cysteine residues are unique in TN-X and 
lack the additional cysteine residues found in tenascin and re- 
strictin which may permit assembly of higher-order b achion 
structures. Exon 2 encodes a series of 18.5 EGF-like repeats 
that are 55 % similar to the 13.5 EGF-like repeats oftenascin. 
Exons 3-34 encode a series of 29 repeats resembling Fn 
IN repeats (aligned and compared in Fig. 4). The second re- 
peat (exons 5 and 6) and the last three repeats (exons 29-34) 
are each encoded by a pair of "split exons y Splitting of Fn 
IN repeats into two exons is also seen in the genes for chicken 
(52) and human tenascin (16). The maximum similarity be- 
tween tenascin and TN-X Fn Ill repeats is in the 3' split 
exons, but is only 40 %. This region encodes a cell-binding 
domain (tenascin repeat 14), identified by Spring et al. (52), 
but the most similar Fn ITI repeat in TN-X (xxviii) is only 
34% similar. Unlike the tenascin (or restrictin) genes, re- 
The Journal of Celt Biology, Volume 122, 1993 272 
I 




V I I  




X I I  
X I I I  
X IV  
XV 
XVI  
XVI I  
XVI I I  
X IX  
XX 
XXI  
XXI I  
XXI I I  
XX IV  
XXV 
XXVI  
XXVI I  
XXVI II 
XX IX  
1 I0 20 30 40 50 60 70 80 90 i00 i i0 120 
I I I I I I I I I I I I I 
V I D GP QD LRWSVTP TTLE LGWLRP QAEVDRFVVSY . . . . . . . . . . . . .  VSADNQRVRLEVP ET  DGTLLT  DLMP GVE~AERGRAVSYPASVRANT 
gppr lge l tv t  drt  sds l l l rwtvp~gef  ds fv iqy  . . . . . . . . . . . . .  kdrdgqpqvvpvegpqr  sav i t  s 1 DPGRKYKFVLYGFVGKKRHGPLVAEAK I 
LP QSDP SPGTPPRLGNLWVTDPTPDSLHLSWTVPEGQFDTFMVQY . . . . . . . . . . . . .  RDRDGRPQVVPVEGPERSFVVS SLDPDHKYRFTLFGIANKKRYGPLTADGTT 
APERKEEpp RP EFLE  QP ~ LTVTGVTP D SLRLSWTVAQGPFDSFMVQY . . . . . . . . . . . . .  KDAQGQP QAVPVAGDENEVTVP GLDP DRKYKMNLYGLRGRQRVGP E SVVAKT 
DPQPHRTGTEAPESPEEP LLGELTVTGSSPDSLSLFWTVPQGSFDSFTVQY . . . . . . . . . . . . .  KD RDGRP RAVRVGGKE SE%~I~/GGLEP GHKYKMHLYGLHEGQRVGPVSAVGLT 
LEPRLGELTVTD I TP DSVGLSWTVPEGEFDSFVVQY . . . . . . . . . . . . .  KDRDGQPQVVPVAADQREVT IPDLEP STKYKFLLFG I QDGKRRSPVSVEAKT 
• . . A ILSWTVPEGQFDSKVVQF . . . . . . . . . . . . .  KDKDGQPQVVPVEGHERSVTVTPLDAGRKYRFLLYGLLGKKRHGPLTADGTS 
r GEGHSLQVT VTQNSVGLSWTVP EGQF DSFVVQY . . . . . . . . . . . . .  KDRDGQPQVVPVEGSLREVSVPGLDPAHRYKLLLYGLHHGKRVGP I SAVAI T 
APEPHLGELTVEEATSHTLHLSWMVTEGEFDSFE I QY  . . . . . . . . . . . . .  TDRDGQLQM~RI  GGDRND ITLSGLESDHRYLVTLYGFSDGKHVGPVHVEALT  
EPPTATPEPP  I KPRLGELTVT DATP DSLSLSWTVPEGQFDHFLVQY . . . . . . . . . . . . .  RNGDGQPKAVRGPGHEEGVT I SGLEP DHKYKMNLYGFHGGQRMGPVSVVGVT 
AAEEETPSPTEPSb~APEPAEEPLLGELTVTGSSPDSLSLSWTVPQGRFDSFRVQY . . . . . . . . . . . . .  KDRDGRPQVVRVGG.  . . 
PEEESPDAPLAKLRLGQMTVRDITSDSLSLSWTVPEGQFDHFLVQF . . . . . . . . . . . . .  KNGDGQpKALRVPGHEDG.  • . 
AEEETP SPTEPS~EPPEEP  LLGELTVTGSSPDSLSLSWTVP QGRFDSFTVQy . . . . . . . . . . . . .  KDRD GRP QVVRVGGEE SEVTVGGLEP GRKY LMHLYGLHEGRRVGPV SAVGVT 
EPGTEAPEPPEEP  LLGELTVTGSSP DSLSLSWTVP QGRFDSFTVQY . . . . . . . . . . . . .  KDRD GRP QAVRVGGQE SKVTVRGLEP GRKYKMHLYGLHEGRRLGPV SAVGVT 
EDEAETTQAVPTMTPEPP  I KPRLGELTMTDATP DSLSLSWTVPEGQFDHFLVQY . . . . . . . . . . . . .  RNGDGQPKAARVPGHEDGVT I SGLEP DHKYKMNLYGFHGGQRVGP I SV IGVT 
EEETP  SPTELSTEAPEPPEEP  LLGELTVTGS SPDSLSLSWT IP QGHFDSFTVQY . . . . . . . . . . . . .  KD RD GRP QVMRVRGEERQVTVGGLEP GRKYKMHLYGLHEGRRVGPVSTVGVT 
EDEAETTQAVPTTTPEPPNEP SLGELTVTDATP DSLSLSWMVR-GQFDHFLVQY . . . . . . . . . . . . .  RNGDGQPKVVRWPGHEDGVT I SGLEPDHKYIq4NLYGFHGGQRVGP I SV IGVT 
AAEEETPAP TEP STEAPEPPEEP  LLGELTVTGS SPDSLS LSWT IPQGRFDSFTVQY . . . . . . . . . . . . .  KDRDGRPQVVRVRGEE SEVTVGGLEP GRKYKMHLYGLHEGQRVGPV SAVGVT 
APEDEAETTQAVPTTTPEPPNKPRLGELTVTDATPDSLSLSWMVPEGQFDHFLVQY . . . . . . . . . . . . .  RNGDGQPKVVRWPGHEDGVT I SGLEP DHKYKMNLYGFHGGQRVGPVSAIGVS 
EEETP  SPTEPSTEAPEAPEEP LLG~LTVTGSSP DSLSLSWTVPQGRF DSFTVQY . . . . . . . . . . . . .  KDRDGQPQVVRVRGEE SEVTVGGLEP ~LYGLHEGQRVGPV S TVG I T 
APLPTPLPVEPRLGELAVEAVTSDSVGLSWTVAQGPFDSFLVQY . . . . . . . . . . . . .  RDAQGQPQAVPVSGDLRAVAVS GLVPARKYKF  LLFGLQNGKRHGPVPVEART 
APDTKP SPRLGELTVTDATPDSVGLSWTVPEGEFDSFVVQY . . . . . . . . . . . . .  KDKDGRLQVVPVAANQREVTVQALEP SRKYRFLLYGLS GRKRLGP I SADST T 
APLEKELPPHLGELTVAEETSSSLRLSWTVAQGPFDSFVVQY . . . . . . . . . . . . .  RD TDGQPRAVPVAADQRTVTVE DLEP GKKYKF  LLYGLLGGKRLGPVSALGMT 
APEEDTPAPELAPEAPEPPEEPRLGVLTVTDTTP DSb~LSWSVAQGPFDSFVVQY . . . . . . . . . . . . .  EDTNGQPQALLVDGDQSK I LI  SGLEP STPYRFLLYGLHEGKRLGPLSAEGTT 
GLAPAGQTSEESRP RLSQLSVTDVTTSSLRLNWEAPPGAF DSFLLRFGVP SP STLEPHPRPPRP LLQRELMVPGTRHSAVLRDLRSGTLYSLTLYGLRGP HKADSI  QGTARTLSP  
VLESPRDLQFSE I  RETSAKVNWV~PPSRADSFKVSY . . . . . . . . . . . .  QLADGGE P QSVQVDGQARTQK LQGL I P GARYEVTVVSVRGFEE SEP LTGFLTT  
VPDGP TQLRALNLTEGFAVLHWKPP QNPVDTYD IQV . . . . . . . . . . . . .  TAPGAPPLQAETPGSAVDYP LHDLVLHTNYTATVRGLRGPNLTSPASI  TFTT 
GLEAP RDLEAKEVTP RTALLTWT EP PVRP AGYL  LSF . . . . . . . . . . . . .  HTPGGQNQE I LLPGGI  TSHQLLGL~ STSYNARLQAMWGQSLLPPVST SFTT 
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Figure 4. (A) Sequence alignment of the Fn HI repeats. Repeats 
were aligned manually using the highly conserved leucine, trypto- 
phan, and tyrosine residues (*). Missing data are indicated by 
(.. .);  gaps by (-);  and identity at a position in 20 or more repeats 
by (!). The sequence of repeat iii previously reported but not 
verified by us is shown in small letters; repeat ii has only been 
identified by hybridization, and has not been sequenced (30)• This 
alignment requires fewer gaps than that proposed by Matsnmoto et 
al. (31). (B) Phylogenetic tree of Fn HI repeats obtained with the 
PAUP program. An heuristic search was performed on 28 repeats 
based on the alignment inA and using the Dayhoff cost matrix. Ini- 
tial trees were obtained by stepwise addition using closest neigh- 
bors, and the most parsimonious trees were found by tree bisec- 
tion/reconnection. The consensus ofthe six trees identified by this 
process is depicted. Numbers are percentage of trees containing 
each bifurcation. 
peats viii and ix of the XB gene are encoded by a single exon 
(Figs. 1 and 2). To our knowledge, such a "fused exon" has 
not been described in other genes encoding proteins with Fn 
III repeats. Each of the other 24 repeats i  encoded by a sin- 
gle exon. The encoded amino acid sequences of the Fn IN 
repeats uggests a series of evolutionary duplication events 
(Fig. 4 B). The dendrogram shows that Fn 111 repeats at the 
amino-terminal end (i-ix) and at the carboxy-terminal end 
(xxiv-xix) diverged earlier in evolution, while the repeats in 
the middle of TN-X arose more recently. Exons 35-39 en- 
code the carboxy-terminal fibrinogen-like domain and the 
Y-untranslated region. Exon 39 overlaps the P450c21B gene 
(39). The carboxy-terminal fibrinogen-like domain is widely 
conserved in evolution (2, 60), and the sequence and in- 
tron/exon structure of the 3' end of the XB gene is very simi- 
lar to the structure of the genes for the t~ and 7 chains of 
fibrinogen (43). This domain is 54 % similar in human tenas- 
cin and TN-X. 
Cellular Expression of TN-X 
Expression of the XB gene encoding TN-X can be evaluated 
by highly specific RNase protection assays. We used a 
single-stranded probe from a region (Fn HI repeat xxiii) that 
lies beyond the limit of duplication of this locus; hence, it 
will not hybridize to and be protected by XA mRNA species. 
This probe has <50% nucleotide sequence identity with the 
corresponding region of tenascin, so that tenascin mRNA is 
not detected. As shown in Fig. 5, the XB gene encoding 
TN-X is expressed atvarying levels in all tissues examined, 
with greatest expression i  fetal testis and in fetal smooth, 
striated, and cardiac muscle. 
An unusual feature of this genetic system is that all of these 
overlapping RNA transcripts are expressed ina single tissue, 
the adrenal cortex. The P450c21 mRNA and the four Y tran- 
scripts (YA-short, YA-long, YB-short, YB-long) (4) all over- 
lap the XA and XB transcripts. To determine whether these 
overlapping transcripts are all expressed in the same cells, 
we performed in situ hybridization histochemistry experi- 
ments using probes for P450c21, Y, XA, and XB. All of the 
probes homogeneously and diffusely stain adult human adre- 
nal cortex (Fig. 6). The P450c21 probe is a 0.7-kb Kpnl/ 
EcoRI fragment of our human P450c21 cDNA (32) that ex- 
cludes XA or XB sequences; because all Y transcripts con- 
tain the entire P450c21 sequence (4), it is not possible to 
construct a P450c21 probe that excludes Y. Fig. 6 A shows 
that P450c2UY is ubiquitously expressed in all cells of the 
adrenal cortex, but not in the adrenal capsule. The XB probe 
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Figure 5. The tissue distribution of TN-X mRNA expression. Sam- 
ples of 20/zg of RNA from various tissues from 20-22-wk-old 
human fetuses were assayed by RNase protection using a sin- 
gle-stranded 500-bp riboprobe transcribed from a 1.4-kb BglII 
genomic fragment encompassing Fn III repeat xxiii. Note that the 
protected 180-bp fragment is seen in all samples; how ver, the level 
of expression varies widely among tissues, and is greatest in fetal 
testis, gut (small intestine, mostly smooth muscle), muscle (stri- 
ated), and heart (whole). 
is a single-stranded copy of a 353-bp PstI fragment that en- 
compasses exon 23 (Fn HI repeat xxi, bases 19,006-19,368 
in Fig. 2). This exon lies 3-kb upstream from the cap site of 
the XA transcript, and has only ~50% nucleotide sequence 
identity with any portion of XA; hence this probe is specific 
for XB. Fig. 6 B shows that >90% of ceUs in the adrenal cor- 
tex also contain XB (TN-X) mRNA, and that there is sub- 
stantial TN-X expression i the connective tissue of the cap- 
sule. The XA and Y probes are the opposite strands of a 
238-bp SacI fragment extending from bases 2,390 to 2,628 
in the XA gene sequence (Fig. 3 A in reference 14); because 
this sequence lies in the region corresponding to intron 26 
in XB (bases 22,876-23,114 in Fig. 2), it is not found in XB 
(TN-X) mRNA, so that one strand of the probe is specific 
for XA and the other is specific for Y. Fig. 6 C shows that 
all cells of the adrenal cortex also contain XA RNA, and 
Panel D shows that Y RNA is also expressed homogeneously 
throughout the adrenal cortex, but, as with P450c21, neither 
XA nor Y is expressed by the adrenal capsule. As each of 
these four probes hybridizes with RNA in over 90% of the 
adrenocortical cells, all of these transcripts appear to be ex- 
pressed in most adrenocortical cells. 
As indicated by the RNase protection experiment in Fig. 
5, TN-X is widely expressed in human fetal tissues, includ- 
ing the adrenal. In Fig. 7 A, a 400-bp probe from repeats 
xxvi and xxvii that detects transcripts from both the XB and 
XA genes diffusely hybridizes to RNA throughout the hu- 
man fetal adrenal cortex. Similar diffuse hybridization is 
seen with probes for Y (Fig. 7 B), the cholesterol side-chain 
cleavage nzyme, P450scc (Fig. 7 C), and P450c21 (Fig. 7 
D). Thus the pattern of expression of the P450c21/X/Y genes 
is similar in both the adult and fetal adrenal cortex. 
Discussion 
Overlapping Genes and Polygenes 
Overlapping genes occur commonly in prokaryots, bacterio- 
phages, and viruses, but only a few examples have been de- 
scribed in higher eukaryotes. These include a cardiac- 
specific gene on the opposite strand of the gene for rat 
hypothalamic gonadotropin-releasing hormone (D two Dro- 
sophila loci (18, 51), a mouse locus of unknown function 
(59), a member of the c-erb-A gene family on the opposite 
strand from the gene encoding rat (28) and human (37) thy- 
roid hormone receptor, and transcripts on the opposite 
strand of rat TGF-/33 (44) N-myc (27), and routine p53 
(24). In prokaryotic systems, overlapping enes encoding 
"antisense" RNAs often are involved in gene regulation (for 
review see references 20 and 50); the roles of overlapping eu- 
karyotic genes are now being studied. 
All of these overlapping ene systems described to date 
consist of only two transcripts. By contrast, the TN-X/ 
P450c2UY system appears to be the first eukaryotic example 
of three linked, overlapping enes: a "polygeneY It is not 
wholly surprising that such a complex was first discovered 
in the HLA class HI region. This region of the genome ap- 
pears to be a hot spot for genetic recombination, as evi- 
denced by the highly allelic nature of the HLA locus in 
general, and by the very high incidence of gene conversion 
events in the P450c21 and C4 loci (for reviews and references 
see references 35 and 38). This may have contributed tothe 
very high density of genes in this region: as shown in Fig. 
1, little intragenic DNA separates the various known tran- 
scriptional units in this locus. 
Studies with antisense oligonucleotides, antisense RNAs 
generated invitro, and transfected antisense genes (reviewed 
in reference 54) indicate that he abundance ofan mRNA and 
its encoded protein can be decreased by introducing exoge- 
nous antisense sequences, presumably by a mechanism 
dependent on RNA/RNA hybridization (21, 25). However, 
endogenously produced antisense RNAs differ from these 
experimental systems in two important ways. First, hetero- 
duplexes of mRNA and synthetic DNA expose the RNA 
component to rapid degradation by RNase H-like activities 
(9, 56); this would not occur with endogenously produced 
antisense RNA transcripts. Second, experimental inhibition 
of gene expression generally requires a large molar excess 
of the antisense sequence, probably because synthetic single- 
stranded oligonucleotides are unstable in vivo (25). How- 
ever, antisense nucleotides are stabilized by integration i to 
an open reading frame or by polyadenylation (10, 19). Hence 
endogenously produced P450c21B/TN-X duplexes or TN- 
X/Y duplexes are likely to be much more stable than are cor- 
responding synthetic experimental systems. Our in situ hy- 
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Figure 6. Darkfield pho- 
tomicrographs of in situ hy- 
bridization histochemistry. A 
frozen surgical sample of hu- 
man adult adrenal was sec- 
tioned and hybridized with 
the following probes: (A) 
P450c21 eDNA fragment that 
excludes XA and TN-X se- 
quences; (B) a fragment of 
TN-X eDNA that does not 
overlap P450c21, XA, or Y; 
(C) a 5' fragment of XA 
eDNA that excludes TN-X, 
P450c21 and Y; and (D) a 
fragment of YA eDNA that 
hybridizes to both YA and YB, 
but not to P450c21, XA, or 
TN-X sequences. The non- 
hybridizing "holes" in each 
photograph are due to holes in 
the desiccated frozen surgical 
sample. An opposite strand 
TN-X sense probe is used as a 
control in panel E Because of 
the overlapping nature of the 
other transcripts, the controls 
in E, G, and H are sections 
treated with RNase A before 
hybridization with eDNAs for 
P450c21 (E), XA (G), and Y 
(/-/). All photomicrographs 
were taken at the same 
magnification. Bar, 200 ~m. 
bridization histochemistry experiments show that P450c21B, 
XB, and Y are all expressed in the same fetal adrenocortical 
cells. Thus, formation of such RNA duplexes in vivo is pos- 
sible. 
Some such endogenously produced antisense systems have 
been studied. N-myc and its antisense transcript form dou- 
ble-stranded hybrids in vivo, which influence N-myc mRNA 
processing (29). In contrast, the antisense transcript of p53 
prevented normal translocation of p53 mRNA to the 
cytoplasm in murine erythroleukemia cells (24). Kimelman 
and Kirschner (26) described a small transcript arising from 
the opposite strand of the gene encoding Xenopus basic FGE 
This antisense transcript encoded aprotein, but also directly 
interacted with the sense transcript converting half of the hy- 
bridized adenine residues to inosine, thus changing the infor- 
mational content of the sense transcript. However, we have 
found no evidence of such RNA editing in the P450c21/ 
TN-X/Y system. 
Tenascins 
Tenascin was first described as an extracellular matrix pro- 
tein in tendons and muscle and later in developing chick 
brain. It has been variously termed GMEM, tenascin, 
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Figure Z Dark_field photomicrographs of in situ hybridization 
histochemistry of human fetal adrenal sections. The probes used 
are: (A) a 350-bp HinclFPstI probe that detects transcripts from ei- 
ther the XB or XA genes; (B) the same Y-specific probe used in 
Fig. 6 D; (C) a 1.2-kb fragment of human P450scc eDNA (8); (D  
the same P450c21 probe used in Fig. 6 A. The controls for the fetal 
tissues are the same as in Fig. 6, and are not shown. All pho- 
tomicrographs were taken at the same magnification. Bar, 100 #m. 
cytotactin, J1, hexabrachion, and myotendinous antigen (re- 
viewed in reference 11). Elucidation of its gene, mRNA, and 
protein structure revealed that the protein is a polymer of six 
chains, each comprising a carboxy-terminal fibrinogen-like 
domain, a series of Fn [ ]  repeats, a series of EGF-like 
repeats, and an amino-terminal ~head group" that permits the 
chains to aggregate into the characteristic "hexabrachion" 
seen in electron micrographs (52). The closely related pro- 
tein restrictin (42), also termed Jl-160 (13), is a trimer com- 
posed of similar but considerably smaller units: a "tri- 
brachionY The XB gene described in this report encodes a
similar but much larger protein that we term tenascin-X, or 
TN-X. Although there is no direct evidence to date, we pre- 
dict that TN-X will also polymerize into a "brachion" com- 
prising an unknown number of arms. We suggest that this 
category of proteins be termed "brachions" or "tenascins7 
We favor the latter. Tenascin, the first-described member, 
which is also widely termed "cytotactin," would be termed 
tenascin-C or TN-C to designate tenascin-cytotactin; res- 
trictin would be termed tenascin-R or TN-R; and the product 
of the XB gene described in this paper would be tenascin-X 
or TN-X. This system would emphasize the relatedness 
among the monomeric units of these proteins and would, to 
the extent possible, incorporate rminologies and letterings 
favored by various groups. It seems unlikely that he number 
of tenascins will exceed the confines of the alphabet. 
TN-X protein appears to have well-conserved heptad re- 
peats capable of forming alpha helices. For TN-C and TN-X, 
the heptads appear to allow three polypeptides to form a tri- 
pie coiled-coil which is stabilized by the flanking cysteine 
residues (46, 52). One interesting difference between TN-X 
and other members of this gene family is the sequence diver- 
gence at the extreme amino terminus of the mature protein. 
This region appears to mediate dimerization of or TN-C 
trimers joined in the heptad region to form the final hexa- 
brachion. Cysteine residues are notably absent from this re- 
gion of TN-X, and hence we predict hat TN-X may form 
pairs or trimers, but not higher order polymers. While the 
aw_ilable lectron microscopic data show no heterogeneity n 
the lengths of the arms of TN-C and TN-R, it might be possi- 
ble for monomers of TN-C, -R, and -X to form hetero- 
polymers. 
Several other features of TN-X merit comment. Unlike 
TN-C and TN-R, which are heavily glycosylated, TN-X has 
only five Asn-X-Ser (Thr) sites for N-linked glycosylation 
(Fig. 2). Whether this difference inthe potential for glycosyl- 
ation will confer unique biological properties to TN-X is not 
known. In addition, both TN-C and TN-R mRNAs undergo 
alternate splicing to yield different sized mRNAs and pro- 
teins. Because most of our structural data come from geno- 
mic DNA rather than from eDNA copies of mRNA mole- 
cules, we have no data to confirm or deny alternate splicing 
of TN-X. Finally, unlike human and chicken TN-C, TN-X 
does not contain an RGD sequence, and hence cannot bind 
to an RGD-dependent receptor. Recent evidence suggests 
that TN-C binding is not limited to the domain carrying the 
RGD sequence (46, 52). RGD-independent binding is consis- 
tent with the lack of an RGD sequence inmouse TN-C (57). 
Overall, there is greater sequence similarity among the 29 
Fn [ ]  repeats of TN-X (Table I) than among the 15 Fn [ ]  
repeats of TN-C (15) or the 9 Fn I1/repeats of TN-R (42). 
Our phylogenetic analysis of Fn [ ]  repeats in TN-X and 
Gulcher's imilar analysis of TN-C (15) suggest a recent 
reduplication ofcentral Fn [ ]  repeats in these genes that has 
not occurred in TN-R. Table I shows that 15 of the 20 central 
Fn [ ]  repeats of TN-X (iv-xxiii) are most similar to repeat 
V of TN-R. This suggests that the central repeats of TN-X 
arose by duplication of the exon encoding the homolog of 
TN-R repeat V in the ancestral progenitor gene. These find- 
ings support amodel in which TN-C, TN-R, and TN-X arose 
from a smaller primordial gene r sembling TN-R, and that 
subsequent internal reduplications produced the central 
repeats of TN-C and TN-X after their divergence from one 
another. For TN-X, frequent duplication might be expected 
given the high incidence of genetic rossover and homolo- 
gous recombination events in the MHC region of chromo- 
some 6 (reviewed in reference 38). These events have led to 
homogenization f duplicated sequences in this region such 
as C4A and B, P450c21A and B, and the various Fn [ ]  re- 
peats of TN-X. 
No functional studies have been done to date on TN-X. 
However, previous tudies of TN-C using polyclonal anti- 
bodies may have identified mixed populations of TN-C and 
TN-X. Our RNase protection experiments unambiguously 
establish that he TN-X mRNA is expressed innearly all tis- 
sues, and is especially widely expressed in developing fetal 
tissues. It is conceivable that antibodies raised against TN-C 
might cross-react with TN-X (which might not be detected 
in Western blotting studies because of its size). Thus, previ- 
ous studies of the functional role of tenascin based on im- 
munologic reagents may need to be re-examined in the light 
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Table L Relatedness of Fnlll Repeats in the Tenascins 
TN-X repeat 1 3 4 5 6 7 8 9 10 11 
Most similar: TN-X 5 8 3 21 14, 19 23 3, 23 8 11, 18 16 
Percent Identity 31 66 65 72 90 73 (66) 63 51 92 
Most similar: TN-C 1 8 12 6 8 8 12 12 12 12 
Percent Identity 31 35 35 35 35 34 (31) 33 33 34 
Most similar: TN-R 4 6 5 5 1 5 5 6 6 5 
Percent Identity 37 27 26 35 30 27 (22) 28 24 31 
12 13 14 15 16 17 18 19 20 21 
Most similar: TN-X 14 12 15 14 11 19 20 21 18 19 
Percent Identity (99) (88) 93 93 92 93 93 96 93 96 
Most similar: TN-C 8 7 8 12 8, 12 8 8 8 12 8 
Percent Identity (46) (21) 36 34 33 37 31 36 34 35 
Most similar: TN-R 5 3 1 5 5 5 5 5 5 5 
Percent Identity (21) (19) 30 33 30 33 31 31 27 31 
22 23 24 25 26 27 28 29 
Most similar: TN-X 5, 7 7 7 24 11 1, 29 1 28 
Percent Identity 65 73 65 61 53 27 31 29 
Most similar: TN-C 9, 12 10 9 9 8 13 14 15 
Percent Identity 33 33 30 39 30 43 34 42 
Most similar: TN-R 5 5 9 9 4 6 7 9 
Percent Identity 30 28 28 28 26 35 32 36 
The alignment of FnIII repeats in Fig. 4 A was used to calculate percent identity of each repeat with the repeat it most closely resembles. Identity figures for 
incompletely sequenced repeats of TN-X are in parentheses; these figures may not be representative. Each TN-X repeat was also aligned with the most similar 
Fn HI repeat of human tenascin and chicken restrictin, and percent identity calculated. 
of the newly established existence of another, very similar, 
and widely expressed protein. 
Crucial insights into function can come from deletion 
mutants-either created in the laboratory or spontaneously 
occurring in nature. The C4/P450c21/Gene X locus has been 
the subject of intensive genetic study because of its associa- 
tion with human disease, and especially with congenital 
adrenal hyperplasia (35, 36, 38). Among 811 informatively 
studied human chromosomes bearing mutated alleles caus- 
ing congenital drenal hyperplasia, 156 had large gene dele- 
tions and another 46 had other genetic rearrangements, yet
none of these chromosomes has a deletion extending into the 
XB gene encoding TN-X (38), suggesting that TN-X may be 
necessary for survival. 
Examination of the duplication junctions of the C4/ 
P450c21/Gene X locus clearly shows that the duplicated hu- 
man, bovine, and murine loci have different boundaries, ug- 
gesting gene duplications and genetic rearrangements that 
postdate mammalian speciation (14). Therefore, it is dif- 
ficult to extrapolate from mouse genetics to human genetics 
in this locus. In the mouse, the P450c21A gene rather than 
the B gene encodes 21-hydroxylase, while in cattle, both 
genes are functional. In the mouse genome, the distance 
from P450c21A to C4B is about 60 kb, possibly enough 
room to accommodate a functional TN-X gene, whereas the 
corresponding human XA gene is truncated and does not en- 
code a tenascin-like protein (14). Homozygous deletion of 
the TN-C gene in mice by gene knockout results in pheno- 
typically normal mice, suggesting that TN-C has no ir- 
replaceable function in the mouse (48). The ubiquitous ex- 
pression of TN-X in the fetus makes TN-X a logical 
candidate to assume the presumed biological function of 
TN-C. Mice lacking an 80-kb fragment extending from 
P450c21A to C4B, which may contain the mouse homolog 
of TN-X, can only be bred as heterozygotes; the homozygous 
condition is lethal (49). Thus it is possible that TN-X, and 
not TN-C, is the tenascin essential for development. 
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